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  Introduction 
 
1. INTRODUCTION 
1.1. The history of MIF 
 
 Macrophage migration inhibitory factor (MIF) was one of the first cytokines to be 
identified (Bloom and Bennett, 1966; David, 1966). MIF was first described as a T cell-
derived cytokine that inhibits the random migration of macrophages. Between 1970 and 1989, 
MIF was reported to enhance monocyte and macrophage functions. However, biological 
activities of MIF remained uncertain until the cloning of the human MIF gene was achieved in 
1989 (Weiser et al., 1989). In 1991, research for new regulators of inflammation led to re-
discovery of MIF as a molecule released, similar to a hormone, by cells of the anterior 
pituitary gland after exposure to the endotoxin lipopolysaccharide (LPS) (Bernhagen et al., 
1993). This important observation indicated that MIF could be a mediator that links the 
endocrine and immune systems. Within a few years, bio-active recombinant MIF proteins and 
neutralizing antibodies were produced and a proinflammatory profile of MIF by acting or 
promoting cytokine expression has emerged (Bernhagen et al., 1994). Interestingly, it was 
observed that low levels of glucocorticoids promote MIF release from monocytes and 
macrophages (Calandra and Bucala, 1995), which was opposed by the concept that MIF is a 
proinflammatory cytokine and glucocorticoids usually exert powerful anti-inflammatory 
actions. MIF then was found to be acting in an autocrine or paracrine manner within the host-
defence system to block the effects of glucocorticoids on LPS-induced cytokine release 
(Bacher et al., 1996). Studies concerning the molecular mechanism of MIF revealed that the 
influence between the pro- and anti-inflammatory actions of MIF and glucocorticoids appear 
to act as a counterregulatory system that aids the maintenance of homeostasis (Bucala, 1996; 
Barnes and Karin, 1997).  
 Using X-ray crystallography the crystal form and unique ribbon structure of rat and 
human MIF was defined in 1996 (Muhlhahn et al., 1996; Sugimoto et al., 1996; Suzuki et al., 
1996). The three dimensional structure and its resemblance to prokaryotic enzymes pointed to 
a potential enzymatic activity of MIF. Later, MIF has been reported to have two different 
catalytic activities: tautomerase (Bendrat et al., 1997; Rosengren et al., 1997; Swope et al., 
1998) and thiol-protein oxidoreductase (Kleemann et al., 1998a; Kleemann et al., 1998b; 
Kleemann et al., 1999). MIF-knockout mice were generated in 1999 and reported to be 
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healthy (Bozza et al., 1999). After 2000, several functions of MIF were described by different 
studies mentioned below.  
1.2. MIF-mediated signaling pathways 
1.2.1. MIF-mediated ERK1/ERK2 activation 
 
 MIF was found to activate extracellular signal-regulated kinase 1 (ERK1)/ERK2, 
members of the family of mitogen-activated protein kinases (MAPKs) (Mitchell et al., 1999). 
MIF-induced activation of ERK1/ERK2 was dependent on protein kinase A and associated 
with increased cytoplasmic phospholipase A2 (PLA2) enzyme activity. PLA2 is an important 
intracellular link in the activation of the pro-inflammatory cascade, resulting first in the 
production of arachidonic acid and then of prostaglandins and leukotrienes. PLA2 also is a 
key target of the anti-inflammatory effects of glucocorticoids. ERK1/ERK2-mediated 
induction of PLA2 is one mechanism where MIF could override the immunosuppressive 
effects of steroids (Mitchell et al., 1999). 
The extracellular domain of CD74, the cell-surface form of the MHC class-II-
associated invariant chain has been reported to bind MIF (Leng et al., 2003). CD74 was 
involved in many activities of MIF such as activation of ERK1/ERK2, cell proliferation and 
the production of prostaglandin E2 (PGE2). However, the intracellular domain of CD74 does 
not contain motifs that can interact with signal-transducing molecules. Therefore the question 
arises whether CD74 would be the unidentified receptor for MIF.   
1.2.2. MIF inhibits p53 activity 
  
An interesting study indicating that MIF works as a negative regulator of p53-
mediated growth arrest and apoptosis has provided a link between MIF, inflammation, cell 
growth and tumorigenesis (Hudson et al., 1999). Following this finding, it was reported that 
the proinflammatory function and the viability of MIF-deficient macrophages were 
diminished compared with wild-type cells after incubation with LPS (Mitchell et al., 2002). 
NO was thought to be a crucial mediator of increased apoptosis in MIF-deficient macrophages 
stimulated with LPS, although MIF-deficient and wildtype macrophages produced equal 
levels of NO. Indeed, MIF was found to inhibit NO-induced intracellular accumulation of 
p53. Inhibition of p53 by MIF required serial activation of ERK1/ERK2, PLA2, 
cyclooxygenase 2 (COX2) and PGE2. In parallel to these results, MIF was reported to interact 
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with the E2F–p53 pathway to sustain normal and malignant cell growth (Petrenko et al., 
2003).  
1.2.3. MIF regulates Toll-like receptor 4 expression 
  
 Toll-like receptor (TLR) plays an essential role in the innate immune response by 
detecting conserved molecular products of microorganisms (Medzhitov et al., 1997; 
Medzhitov, 2001). TLR4 is the receptor for LPS, the major component of the cell wall of the 
gram-negative bacteria (Takeda et al., 2003). MIF-deficient macrophages were found to be 
hyporesponsive to LPS and Gram-negative bacteria, as shown by reduced cytokine production 
due to the downregulation of expression of TLR4 (Roger et al., 2001; Roger et al., 2003). 
MIF upregulates the expression of TLR4 by acting on the ETS family of transcription factors, 
which are crucial for transcription of the mouse TLR4 gene. Therefore, MIF facilitates the 
detection of endotoxin-containing bacteria, enabling cells to respond rapidly to invasive 
bacteria. 
1.2.4. MIF stimulates glycolysis  
  
 An unexpected role for MIF in the regulation of glycolysis was documented with in 
vitro and in vivo studies (Benigni et al., 2000). It was shown that MIF controls peripheral 
glucose metabolism and mediates the catabolic effects induced by severe inflammatory 
responses. The addition of recombinant MIF to differentiated rat muscle cells increased 
synthesis of fructose bisphosphate. In the same study, it is implicated that the catabolic effect 
of TNF-α on muscle cells was mediated by MIF, which served as an autocrine stimulus for 
fructose bisphosphate production. TNF-α administered to mice decreased serum glucose 
levels and increased muscle fructose bisphosphate levels and pre-treatment with a neutralizing 
anti-MIF antibody completely inhibited these effects. Anti-MIF antibody also prevented 
hypoglycaemia and increased muscle fructose bisphosphate levels in TNF-α–knockout mice 
that were administered LPS, supporting the contribution of MIF to these inflammation-
induced metabolic changes. Briefly, MIF was found to be a positive, autocrine stimulator of 
insulin release, suggesting an important role for MIF in the control of host glucose and 
carbohydrate metabolism. 
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1.2.5. MIF inhibits Jab1/CSN5 activity 
  
 An interaction between MIF and c-Jun-activation domain-binding protein 1 (Jab1) 
known as the fifth component of the COP9 signalosome (Jab1/CSN5) was shown by using a 
yeast two-hybrid system (Kleemann et al., 2000). In the same study, it is observed that MIF 
and Jab1/CSN5 are co-localized in the cytoplasm and that MIF inhibits the positive regulatory 
effects of Jab1/CSN5 on the activity of JNK and AP1 (Kleemann et al., 2000). Moreover, 
Jab1/CSN5 was found to activate Jun N-terminal kinase (JNK), phosphorylate c-Jun and 
function as a co-activator of activator protein 1 (AP1), a transcription factor that is involved in 
cell growth, transformation and cell death (Shaulian and Karin, 2002).  
1.2.6. MIF activates the AKT pathway  
 
 Although the inhibition of p53 mediated apoptosis by MIF was indicated (see 1.2.2), 
MIF-induced AKT pathway was also shown to prevent apoptosis and promote cell survival in 
fibroblasts, HeLa cervix carcinoma cells and various breast cancer cell lines (Lue et al., 
2007). The phosphoinositide-3-kinase (PI3K)/AKT signaling pathway plays an crucial role in 
the cellular response to growth factors and regulates key cellular functions such as growth, 
metabolism, migration, apoptosis and survival (Song et al., 2005). PI3K/AKT signalling is 
initiated by activation of receptor tyrosine kinases or G-protein-coupled receptors (Wetzker 
and Bohmer, 2003). Activation of PI3K/AKT causes different cellular responses, but most 
importantly, AKT activation leads cell survival and prevents cell to resist apoptosis. It was 
shown that the MIF-induced AKT pathway transmits signaling through the MIF binding 
protein CD74 and the upstream kinases Src and PI3K. Additionally, MIF-induced AKT 
activation led to inactivation of pro-apoptotic proteins, namely BAD and Foxo3a. In 
agreement with these result, apoptosis inhibition by MIF was abolished by overexpression of 
the AKT pathway inhibitor PTEN showing that this inhibition occurred without assistance of 
p53. Briefly, a cell survival effect of MIF was proven through PI3K/AKT and its downstream 
pathways in fibroblast and different cancer lines. 
1.2.7. MIF regulates leukocyte migration  
 
Although MIF was discovered as an inhibitor of random macrophage migration 
(David, 1966), the mechanisms underlying MIF-regulated cell migration and the proteins 
involved have not been studied for many years. Recent study has revealed that MIF is a 
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functional noncognate ligand for the chemokine receptors CXCR2 and CXCR4, and therefore 
controls inflammatory and atherogenic leukocyte recruitment (Bernhagen et al., 2007).  
In this study, MIF was shown to facilitate chemotaxis of monocytes and T cells, rapid 
integrin activation and calcium influx through CXCR2 or CXCR4. MIF was indicated to 
directly bind to CXCR2 and compete with cognate ligands for CXCR4 and CXCR2 binding. 
The CXCR2 and CD74 interaction found in this study suggested a new signaling pathway via 
a functional CXCR2-CD74 complex. Additionally, in vivo experiments also provided several 
lines of evidence that MIF deficiency diminished monocyte adhesion to the arterial wall in 
atherosclerotic mice and MIF-induced leukocyte recruitment. Briefly, MIF was identified as a 
crucial CXCR2 ligand in advanced atherosclerosis. Blockade of MIF in mice with advanced 
atherosclerosis causes plaque regression and reduced monocyte and T-cell contents in 
plaques. In light of these important findings, chemokine-like functions of MIF and a 
regulatory role in inflammation and atherogenesis were discovered (Bernhagen et al., 2007).   
1.2.8. MIF modulates the activation of AMPK pathway  
  
 MIF was found to exert one of its metabolic effects on AMP-activated protein kinase 
(AMPK) pathway (Miller et al., 2008). AMPK, an important regulator of both glycolysis and 
glucose uptake during cellular stress, protects the heart against ischaemic injury and 
apoptosis. AMPK affects different pathways. For example; AMPK stimulates 6-
phosphofructo-2-kinase activity and glycolysis in the heart (Marsin et al., 2000), induces 
glucose transporter-4 (GLUT4) translocation (Russell et al., 1999), increases ischaemic 
glucose uptake (Russell et al., 2004) and limits myocardial injury and apoptosis (Xing et al., 
2003). MIF is shown to be released in the ischaemic heart, where it stimulates AMPK 
activation through CD74. This stimulation promotes glucose uptake and protects the heart 
during ischaemia-reperfusion injury. MIF germ line deletion impairs ischaemic AMPK 
signaling in the mouse heart. Additionally, MIF release in human fibroblasts and AMPK 
activation during hypoxia were diminished. For these reasons, MIF received new attention as 
a modulator of the activation of the cardio-protective AMPK pathway during ischaemia. 
These results create a link between inflammation and metabolism in the heart. MIF expression 
was also thought to have an impact on the response of the human heart to ischaemia by the 
AMPK pathway.  
 AMPK is known as a potential target molecule for the treatment of many diseases, 
because of its metabolic actions that increase skeletal muscle glucose uptake and suppress 
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hepatic glucose production. AMPK is also a potential molecule in ischemic heart disease, 
because of its cardio-protective effects and potential role in ischemic conditions (Sukhodub et 
al., 2007). For these reasons, it is believed that treatment with MIF or MIF agonist’s might be 
a therapy targeted at AMPK activation during acute myocardial ischemia or infarction. 
1.3. Role of MIF in pathogenesis 
 
 MIF has been shown to participitate in the pathogenesis of several acute and chronic 
inflammatory diseases  as summarized in Table 1 modified from (Lue et al., 2002). 
Table1: Human pathologies associated with MIF in systems and organs 
Pathogenesis      References    
Sepsis and toxic-shock syndrome   (Bernhagen et al., 1993; Bozza et al., 1999) 
Delayed-type hypersensitivity   (Bernhagen et al., 1996) 
Adjuvant and antigen-induced arthritis  (Mikulowska et al., 1997; Leech et al., 1998) 
Glomerulonephritis    (Lan et al., 1996; Yang et al., 1998) 
Acute lung injury    (Makita et al., 1998) 
Allograft rejection    (Brown et al., 1999) 
Inflammatory bowel disease (colitis)  (de Jong et al., 2001) 
Gastrititis, Pancreatitis    (Huang et al., 2001; Sakai et al., 2003) 
Atherogenesis     (Lin et al., 2000) 
Encephalomyelitis    (Denkinger et al., 2003) 
Uveoretinitis     (Kitaichi et al., 2000) 
Systems and organs    Pathogenesis     
Immune system     sepsis, septic shock and allograft rejection 
Lung      adult respiratory distress syndrome, asthma,  
      tuberculosis and Wegener’s granulomatosis 
Kidney      glomerulonephritis 
Bones and joints     rheumatoid arthritis, polychondritis 
Gastrointestinal tract    colitis and Crohn’s disease 
Skin      atopic dermatitis, psoriasis and systemic sclerosis 
Endocrine system    type–2 diabetes and pancreatitis 
Brain      multiple sclerosis and neuro-Behcet’s disease 
Eye      uveitis and iridocyclitis 
Heart and vasculature    atherosclerosis 
Ear      otitis      
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1.4. Cell and tissue distrubition of MIF 
 
 Besides the immune system, MIF has a broad cell and tissue distribution. Previously, T 
cells were thought to be the main cellular source of MIF in the immune system. However, 
many cells such as monocytes, macrophages, blood dendritic cells, B cells, neutrophils, 
eosinophils, mast cells and basophils have been shown to express MIF (Baugh and Bucala, 
2002; Lue et al., 2002). Notably, MIF is expressed by cells and tissues that are in direct 
contact with the host’s natural environment, such as the lung, the epithelial lining of the skin, 
gastrointestinal and genitourinary tracts. Additionally, high levels of MIF expression were 
noticed in several tissues of the endocrine system, especially in organs such as hypothalamus, 
pituitary and adrenal glands (Calandra et al., 1994; Meinhardt et al., 1996; Bacher et al., 1997; 
Fingerle-Rowson et al., 2003).  
1.5. MIF interacting proteins 
 
 Through its interaction with a variety of proteins, MIF display diverse activities in a 
cell. MIF was shown to regulate the activity of JNK and AP1 by directly interacting with 
Jab1/CSN5 (Kleemann et al., 2000). A recent study showed that MIF not only interacts with 
Jab1/CSN5, the fifth component of the COP9 signalosome (CSN) (see 1.6 and 1.7 for details), 
but also CSN6 due to their MPN domain (Burger-Kentischer et al., 2005). Jab1/CSN5 plays 
an important role as a subunit of the CSN complex in animals as well as in plants. The CSN 
complexes interact with SCF (Skp1/Cullin/F-box protein) E3 ubiquitin ligase complex and 
deconjugate Nedd8 from Cullin (Cope et al., 2002). In particular, removal of Nedd8 is carried 
out by the isopeptidase activity that resides in the MPN domain metalloenzyme JAMM motif 
of Jab1/CSN5. This motif is only functional in the content of the CSN complexes (Cope and 
Deshaies, 2006). The deneddylation of Cullin results in increased activity in SCF ligases 
which target p27 and Cyclin E for ubiquitin-dependent proteolysis (Cope and Deshaies, 2003, 
2006). 
 MIF was shown to interact with PAG, a thiol-specific antioxidant. The interaction of 
MIF and PAG showed a reduction of the dopachrome tautomerase activity of MIF (Jung et 
al., 2001). In another study, hepatopoietin (HPO) was found to interact with both MIF and 
Jab1/CSN5, which implicated modulation of the AP-1 pathway (Li et al., 2004).  
Recent work has identified CD74 as a cell surface binding receptor for MIF (Leng et 
al., 2003). However, not all cells targeted by MIF express CD74 on their surface and CD74 
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does not contain an intarcellular domain for signal transduction, so it is suggested that CD74 
could be a docking or an adaptor protein which could present MIF to other proteins.  
Although the direct interaction between insulin and MIF was not defined, co-
localization of insulin with MIF in secretory granules of pancreatic islet and the regulation of 
glucose-induced insulin release was studied (Waeber et al., 1997). More recently, a direct 
interaction of MIF with myosin-light-chain-kinase isoform (MLCK) was identified 
(Wadgaonkar et al., 2005) suggesting a role of MLCK in the regulation of non-muscle 
cytoskeletal dynamics and pathobiologic vascular events.  
1.6. MIF affects the activity of the Ubiquitin Proteasome System (UPS) 
 
A recent investigation has shown that the optimal composition and activity of SCF 
ubiquitin ligases, which are known to play an important role in the UPS, is maintained 
through the Jab1/CSN5-MIF interaction (Nemajerova et al., 2007a). MIF inhibits Jab1/CSN5 
function by preventing it from interacting with other cellular proteins targeted by the COP9 
signalosome (CSN), especially the Cullins (Nemajerova et al., 2007a). Cullin1 belongs to 
SCF (E3 Ubiquitin ligase) which is known to control both the specificity and timing of 
substrate ubiquitinylation. The SCF complex consists of three different components: Rbx1 
(Ring box-1), Cullin1 (Cul1, scaffold protein), Skp1 (adaptor protein) and the F-box family 
proteins, which are responsible for substrate recognition (Cardozo and Pagano, 2004). The 
main catalytic core of SCF is the Rbx1 and Cul1 subunits (Figure 1). The activity of the SCF 
is stimulated by attachment of an ubiquitin-like protein called Nedd8 to the Cullins 
(neddylation) (Bornstein et al., 2006). In a converse manner, deneddylation of cullins was 
achieved by the CSN/COP9 signalosome with the Jab1/CSN5 subunit directly cleaving of 
Nedd8 (Cope et al., 2002). Importantly, deneddylated cullins are segregated by inhibitory 
Cand1 (Figure 1) (Liu et al., 2002). Thus, SCF activity is sustained by dynamic cycles of 
assembly and disassembly, where both inhibitory protein Cand1 and CSN interacting with 
MIF play a negative role (Petroski and Deshaies, 2005). In this context, MIF binding to 
Jab1/CSN5 regulates the cycle and activity of the SCF complex. Briefly, the mechanism how 
MIF affects the activity of the UPS is shown in figure 1. 
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Figure 1: MIF-Jab1/CSN5 interaction regulates SCF activity. 
The SCF E3 ubiquitin ligase is composed of Cullins, Skp1 and F-box proteins. Deneddylation 
(removal of Nedd8 from Cullin1) is achieved by Jab1/CSN5. Following deneddylation of 
Cullins, Skp1 and F-box proteins are replaced by the inhibitory protein Cand-1. MIF binds to 
Jab1/CSN5 and prevents it from interacting with Cullins targeted by CSN. Modified from 
(Nemajerova et al., 2007b). 
 
1.7. The COP9 signalosome (CSN)  
 
 One of the most important regulatory components of the UPS is the COP9 
signalosome (CSN). Deng and co-workers first identified the CSN in Arabidopsis (COP 
stands for constitutive photomorphogenesis) as a suppressor of light-dependent development 
(Wei et al., 1994; Wei and Deng, 1999). The mammalian CSN complex, also known as the 
Jab1/CSN5 containing signalosome, was isolated and co-purified with the 26S proteasome 
(Seeger et al., 1998). 
 CSN fractionates as a 450–550-kDa complex in gel filtration columns and consists of 
eight subunits called CSN1 to CSN8. A characteristic feature of the CSN subunits is the 
presence of two domains known as the PCI/PINT (Proteasome, COP9 signalosome, Initiation 
factor 3/Proteasome subunits, Int-6, Nip-1, and TRIP-15) and the MPN/MOV34 family (Mpr1 
Pad1-N-terminal) domains (Aravind and Ponting, 1998). These two domains are also found in 
three large protein complexes: CSN, the 26S proteasome lid subcomplex, and eukaryotic 
translation initiation factor 3 (eIF3) (Glickman et al., 1998; Wei et al., 1998). The 26S 
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proteasome (see details in 1.8, figure 3) carried out the non-lysosomal protein degradation in 
eukaryotic cells, is composed of the 20S catalytic core particle (CP) and the 19S regulatory 
particle (RP). Remarkably, each of the eight CSN subunits share pair-wise homology with a 
corresponding lid component, suggesting that CSN and the lid may have a common 
evolutionary ancestor. The CSN has several biochemical activities explained below: 
1.7.1. The Metalloprotease Activity of CSN and Deneddylation of SCF 
 
Jab1/CSN5 contains a metalloprotease motif referred to as JAMM (Jab1/MPN 
domain-associated metalloisopeptidase) or MPN+ motif. Mutations in this motif of 
Jab1/CSN5 abolish the activity. Similarly, RPN11, the Jab1/CSN5 paralog in the proteasome 
lid, contains the same JAMM/MPN+ motif, which consists the major de-ubiquitinating 
activity of the 26S proteasome (Verma et al., 2002). Although some other proteins posses 
JAMM/MPN+ (Maytal-Kivity et al., 2002; McCullough et al., 2004; Bellare et al., 2006), 
both Jab1/CSN5 and RPN11 harbor the metalloisopeptidase activity only when they assemble 
into the CSN complex or the 26S proteasome, respectively (Cope et al., 2002). The 
metalloprotease activities of Jab1/CSN5 and RPN11 are likely regulated in accordance with 
other activities of the complex such as deubiquitinylation and deneddylation. 
Another important function of the CSN has received attention in molecular biology. 
Jab1/CSN5 is involved in deneddylation of the SCF complex due to its functional MPN motif. 
The SCF ubiquitin ligase complex is the major target of CSN. SCF represents a type of E3 
(Ubiquitin ligase) enzyme that catalyzes a key step in ubiquitin conjugation to the target 
proteins. Similar to the ubiquitin conjugation pathway, the neddylation pathway is catalyzed 
by an enzymatic cascade involving Nedd8-activating enzymes, whereas deneddylation is 
catalyzed by a metalloisopeptidase activity centered within the Jab1/CSN5 subunit (Cope et 
al., 2002). Active cycles of neddylation and deneddylation are required to maintain the SCF 
activity toward its target substrates.  
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1.7.2. CSN-Associated Protein Kinase Activity and Deubiquitinylation Activity 
 
The CSN was found to phosphorylate c-Jun (Ser63 and Ser73), IκBα and the NF-κB 
precursor, p105, as well as the tumor suppressor p53 (Ser149, Thr 150, and Thr 155) in vitro 
(Seeger et al., 1998; Bech-Otschir et al., 2001). The CSN itself is a target of phosphorylation, 
since phosphorylation sites of some subunits have been noted (Henke et al., 1999). 
 Recently, reports demonstrated ubiquitin isopeptidase activities associated with the 
CSN (Groisman et al., 2003; Zhou et al., 2003; Hetfeld et al., 2005; Schweitzer et al., 2007). 
Deubiquitinylation activities of the CSN are explained in two ways: CSN either deconjugates 
ubiquitin from mono-ubiquitinated substrates or depolymerize the polyubiquitin chains 
(Groisman et al., 2003). The former activity requires the metalloprotease domain in 
Jab1/CSN5 (Groisman et al., 2003), suggesting that cleavage of the ubiquitin- or Nedd8-
monoconjugates shows similar mechanisms, whereas the latter activity is associated with the 
CSN (Zhou et al., 2003; Hetfeld et al., 2005; Schweitzer et al., 2007). Briefly, these findings 
indicate that the CSN has both deneddylation and de-ubiquitinylation activities either by 
possessing activities on their own or by selectively associating different deubiquitinylation 
enzymes. 
1.7.3. Protein degradation 
 
Jab1/CSN5 facilitates the 26S proteasome-dependent degradation of several proteins, 
including p27Kip, Luteinizing hormone receptor (LHR), p53, estrogen receptor, Smad4, 
Smad7, Id1, Id3, and IκBα (Li et al., 2000; Wan et al., 2002; Berse et al., 2004; Kim et al., 
2004; Yun et al., 2004; Callige et al., 2005).  
 
Protein degradation is deployed to modulate the steady-state abundance of proteins 
and to switch cellular regulatory circuits from one state to another by elimination of proteins. 
In eukaryotes, the protein degradation that occurs in the cytoplasm and nucleus is carried out 
by key regulatory proteins via the UPS. Among these regulatory proteins, both CSN (COP9 
signalosome) and VCP control the degradation of certain substrates (Ye et al., 2001; Wei and 
Deng, 2003). 
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1.8. Ubiquitin Proteasome System (UPS) 
 
The UPS has an essential function in eukaryotes by controlling the levels of crucial 
intracellular regulatory proteins. The UPS cycles in two phases; ubiquitinylation and 
degradation. In the initial ubiquitinylation phase, Ub (Ubiquitin) is activated through the 
ATP-dependent formation of a thiol ester with a cysteine residue of Ub-activating enzyme 
(E1), then transferred to a cysteine residue of an Ub conjugating enzyme (E2) and finally, 
transferred to a lysine residue of the substrate in a reaction catalyzed by an Ub-protein ligase 
(E3). Ub is linked to the substrate through an isopeptide bond. The activation and ligation 
reactions involve the carboxyl group of the final amino acid of Ub (G76) (Figure 2) (Pickart, 
2001b, a).  
The attachment of a single ubiquitin molecule (monoubiquitinylation) onto a substrate 
has been assigned to different functions such as lysosomal sorting, endocytosis and trafficking 
(Schnell and Hicke, 2003) (Figure 2).  
 
 
 
Figure 2: Ubiquitin Conjugation and Signalling 
A: Ubiquitin is activated by E1 (Ubiquitin activating enzyme) and subsequently transfered to 
E2 (Ubiquitin conjugating enzyme). The substrate (blue box) and the E2 enzyme both bind 
specificially to E3 (Ubiquitin protein ligase) and the activated ubiquitin is then transferred to 
the substrate. B: The E3 binds its substrate and its specific E2 partner at separate sites. The 
substrate is frequently recognized through an ubiquitinylation signal C: some of the known 
functions of monoubiquitinylation (left) and polyubiquitinylation (right). Lysine 48 (K48) 
linkages recognized by the 26S proteasome for degradation and K63 linkages involved in 
  12   
  Introduction 
multiple pathways, including DNA damage, protein trafficking, ribosomal function and 
inflammation response. From (Pickart, 2001b)  
 
In the second phase of the UPS cycle, the proteasome recognizes the substrate via the 
poly-Ub chain. The substrate is degraded to small peptides and Ub is recovered by specific 
deubiquitinating enzymes. Like conjugation, proteasomal degradation is also ATP dependent. 
The 26S proteasome is a remarkable protein machine that catalyzes the signal-dependent 
unfolding and proteolysis of its substrates (Schwechheimer and Deng, 2001; Pickart and 
Cohen, 2004). It is made up of two kinds of complexes (Figure 3). The 20S core complex is a 
cylindrical stack. It harbors the proteolytic active sites, which face a large interior chamber. 
Substrate unfolding and recognition of polyUb tag are carried out by the 19S complex that is 
located at either end of the 20S complex. Each 19S complex contains 15–20 subunits; 
including six ATPases that are located proximal to the 20S barrel and are likely to promote 
ATP-dependent substrate unfolding and translocation.  
 
 
 
Figure 3: Structural and functional representation of the 26S proteasome.  
The 26S proteasome consists of a 19S regulatory particle (divided into lid and base 
subcomplexes) and a 20S proteolytic core. Functions of each particle are indicated on the 
right side. From (Schwechheimer and Deng, 2001).  
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1.9. VCP dependent proteasomal degradation 
  
 The 97-kDa valosin-containing protein (p97 or VCP) plays essential roles in ubiquitin-
proteaosome proteolysis, which depend on an ability to recognize ubiquitin signals. Ubiquitin 
interaction with VCP and its cofactors play an important role in VCP-regulated processes. 
VCP acts as a chaperone in the UPS, thus regulating the various cellular functions through 
this pathway. VCP is ubiquitous, essential, and highly abundant in cells, accounting for more 
than 1% of the total cellular protein.  
 VCP is a member of the type II AAA (ATPases Associated with a variety of 
Activities) ATPases, which are characterized by the presence of two conserved ATPase 
domains, also called AAA domains (Neuwald et al., 1999; Zwickl and Baumeister, 1999; 
Vale, 2000; Maurizi and Li, 2001; Ogura and Wilkinson, 2001). VCP, also known as VAT in 
archaebacteria, CDC48 in yeast, TER94 in Drosophila, p97 in Xenopus, and VCP in plants 
and mammals is one of the most highly evolutionarily conserved proteins (Frohlich et al., 
1991; Pamnani et al., 1997). 
 VCP molecule is composed of N-terminal domain (N), two ATPase domains (D1 and 
D2), and a C-terminal domain (C). The N domain binds to polyubiquitin chains and thus is 
responsible for substrate recognition. Both D1 and D2 are required for providing the 
chaperone activity (Figure 4) (Wang et al., 2003). 
 
 
 
Figure 4: The structural–functional relationship of VCP domains. 
A: Walker A, B: Walker B and SRH: the Second Region of Homology motifs in D1 and D2 
domains of VCP. From (Wang et al., 2004). 
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 Electron microscopy (EM) studies indicated that VCP has a barrel-like homo-
hexameric structure that comprises two stacked hexameric rings made of the respective AAA 
modules (Wang et al., 2003). 
VCP is involved in many other cellular activities such as cell cycle progression (Cao 
K, 2004), homotypic membrane fusion after mitosis, and disassembly of the spindle at the end 
of mitosis (Kondo et al., 1997; Cao et al., 2003; Wojcik et al., 2004), retrograde translocation 
of misfolded proteins from the ER (Ye et al., 2001; Braun et al., 2002; Jarosch et al., 2002), 
degradation of polyubiquitinated proteins by the proteasomes (Ghislain et al., 1996; Dai and 
Li, 2001), and activation of transcription factors (Hitchcock et al., 2001; Rape et al., 2001) in 
addition to degradation of proteins.  
 VCP, with the help of cofactors, specifically binds the ubiquitinylated protein and 
chaperons the protein before passing it to the 26S proteasome for degradation (Figure 5). 
After substrate ubiquitinylation, VCP likely uses the energy generated from ATP hydrolysis 
to segregate the protein complex, singles the ubiquitinylated protein, and presents it to the 
proteasome for degradation. As an example: in unstimulated cells NF-κB is located in the 
cytoplasm in an inactive form in physicall association with the inhibitory IκB proteins (Karin 
and Ben-Neriah, 2000; Santoro et al., 2003). In response to stimulation, NF-κB can be 
activated and IκBα is rapidly phosphorylated and polyubiquitinylated (Karin and Ben-Neriah, 
2000). Following that, VCP binds the polyubiquitinylated IκBα and likely dissociates it from 
the NF-κB complex (Dai et al., 1998). After dissociation, the NF-κB dimer translocates into 
the nucleus to regulate its target genes. In the meantime, VCP chaperones the 
polyubiquitinylated IκBα to the 26S proteasome for irreversible degradation (Dai et al., 1998). 
In light of this example, figure 5 displays how the ubiquitinylated proteins are guided to the 
proteasome or to other signaling pathways via VCP.  
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Figure 5: A role of the molecular chaperone VCP in the UPS.  
Step 1 shows protein B polyubiquitinylation, which tags the protein for proteasomal 
degradation. In step 2, VCP together with other cofactor(s), binds to protein B via the N 
domain of VCP and the poly-Ub chain on protein B. In step 3, the VCP/cofactor complex 
disassembles the protein A/B complex using the energy generated from VCP-catalyzed ATP 
hydrolysis. Dissociated protein B is then chaperoned to other intracellular locations or to the 
proteasome for degradation (steps 4 and 5), from (Wang et al., 2004).  
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1.10. Aim of the study 
 
Macrophage migration inhibitory factor (MIF) is a ubiquitously expressed, 
predominantly cytoplasmic protein that has been implicated in the regulation of cell growth, 
development and many acute as well as chronic inflammatory diseases (Lue et al., 2002; 
Mitchell, 2004). A search for intracellular MIF-binding partners by the yeast two-hybrid 
system yielded Jab1/CSN5 as MIF interacting protein (Kleemann et al., 2000). MIF binds to 
the metalloprotease MPN domain of Jab1/CSN5 and inhibits Jab1/CSN5 function by 
preventing it from interacting with other cellular proteins. Recent studies point to a regulatory 
role of MIF on the UPS (Nemajerova et al., 2007b) suggesting that MIF controls proteasomal 
activity via inhibiting the deneddylating activity of Jab1/CSN5. Nonetheless, despite this 
recent progress in understanding MIF-mediated signaling pathways, the molecular modes of 
MIF action and the functional partner(s) underlying its role in protein degradation and 
intracellular regulatory systems (specially the UPS and ERAD) remain unclear. By using a 
systematic approach the aim of this study was to identify and characterize of new MIF 
interacting partners and to reveal the relevance of these interactions for cellular functions.  
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2. ABBREVIATIONS  
 
aa    Amino acid(s) 
Amp    Ampicillin 
AMSH    associated molecule with the SH3 domain of STAM  
AP-1    Activator protein 1 
APS    Ammonium persulphate 
ATP    Adenosine 5'-triphosphate 
bp    Base pair 
BSA    Bovine serum albumin 
°C    Degree Celsius 
cDNA    Complementary DNA 
CHAPS   3-[(3-Cholamidopropyl)-dimethyl-ammonio] – propanesulfonate 
COX-2   Cyclooxygenase-2 
COP    Constitutive photomorphogenesis 
cPLA2    cytosolic phospholipase A2 
CXCR2   CXC chemokine receptor 2 
CXXS    Cys-Xaa-Xaa-Cys motif 
DAPI    4’, 6’-diamino-2-phenylindole, dihydrochloride 
DCME    L-dopachrome methylester 
DMEM   Dulbecco’s Minimal Essential Medium 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
DNase    Deoxyribonuclease 
dNTPs    2’-deoxynucleoside-5’-triphosphates 
ds    Double strand 
DTT    Dithiothreitol 
DUB    Deubiquitinase 
E. coli    Escherichia coli 
ECL    Enhanced chemiluminescence 
et al.    and others 
EDTA    Ethylene diamine tetraacetic acid  
ERAD    Endoplasmic reticulum associated degradation 
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ERK1/2   Extracellular signal-regulated kinases 
FCS    Fetal calf serum 
FLAG    N-DYKDDDDK-C (octapeptide) 
FRET     Fluorescence Resonance Energy Transfer 
g    gram or gravity, depending on the context 
GST    Glutathione S-Transferase 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF-1    Hypoxia inducible transcription factor 1 
His    Histidine 
HRP    Horse radish peroxidase 
IPTG    Isopropyl β-D-thiogalactopyranoside 
IEF    Isoelectric focusing 
JAB1    Jun-activation domain-binding protein 1 
JNK    c-Jun N-terminal kinase 
kb    Kilo base pair. 
kD    Kilo Dalton 
LB    Luria Bertani medium 
LPS    Lipopolysaccharide 
M    Molar 
MALDI MS   Matrix-assisted laser desorption ionization MS 
MAPK    Mitogen-activated protein kinase 
mg    Milligram 
MES    Morpholinoethane sulfonic acid 
MIF    Macrophage migration inhibitory factor 
min    Minute 
ml    Milliliter 
mol    Mol 
MOPS    3-(N-Morpholino)-propanesulfonic acid 
mRNA    messenger RNA 
MW    Molecular weight 
n    nano (10-9) 
NaCl    Sodium chloride 
NCBI    National Center for Biotechnology Information 
NHS    Normal horse serum 
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NP-40    Nonidet P-40 
PAG    Proliferation associated-gene 
PAGE    Polyacrylamide gel electrophoresis 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PDGF    Platelet derived growth factor 
PFA    Paraformaldehyde  
PGE2    Prostaglandin E2 
Pgk-1    Phosphoglycerate kinase 1 
pH    -log c[H+] 
PMSF    Phenylmethylsulfonyl fluoride 
PVDF    Polyvinylidenfluorid 
RISC    RNA-induced silencing complex 
RNA    Ribonucleic acid 
RNAi    RNA interference 
RNase    Ribonuclease 
rpm    Revolutions per minute 
RP S19   Ribosomal protein S19 
RT    Room temperature 
SCF    Skp1-Cullin-F-box protein 
SDS    Sodium dodecylsulphate 
sec    Second 
siRNA    short interfering RNA 
shRNA   short hairpin RNA 
ss    single strand 
STAM    signal transducing adaptor molecule 
TAE    Tris-acetate-EDTA 
TAP    Tandem affinity purification 
TBE    Tris-borate-EDTA 
TE    Tris-EDTA 
TEMED   N-N’-N’-Tetramethylendiamin 
TLR    Toll like receptor 
TNF-α    Tumor necrosis factor alpha 
Tris    Tris (hydroxymethyl)-amino-methane 
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U    Unit 
UPS    Ubiquitin proteasome system 
USP15    Ubiquitin specific proteinase 15 
UV    Ultraviolet 
V    Volt 
VCP    Valosin-containing protein 
Vh    Volt hour 
v/v    Volume per volume 
w/v    Weight per volume 
wt    wild type 
µ    Micro 
µg    Microgram 
µl    Microliter 
µM    Micromolar 
  Materials 
3. MATERIALS 
3.1. Chemicals 
 
Acetic acid        Merck, Darmstadt 
Acrylamide 30%      Roth, Karlsruhe 
Agarose       Invitrogen, Karlsruhe 
Bacto-Tryptone      BD Bioscience, Sparks 
Bacto-yeast extract      BD Bioscience, Sparks 
Biotin        Sigma-Aldrich, Steinheim 
Bromophenol blue sodium salt    Sigma-Aldrich, Steinheim 
Calcium chloride      Merck, Darmstadt 
CHAPS       AppliChem, Darmstadt  
Chloroform       Merck, Darmstadt 
Brilliant Blue G-Colloidal Concentrate   Sigma-Aldrich, Steinheim 
Dexamethasone      Sigma Aldrich, Steinheim 
2'-Deoxynucleoside 5'-triphosphate    Gibco, Neu-Isenburg 
Dimethyl sulfoxide      Merck, Darmstadt 
di-potassium hydrogen phosphate    Merck, Darmstadt 
di-sodium hydrogen phosphate    Merck, Darmstadt 
1,4-Dithiothreitol      Roche, Mannheim 
Ethanol       Sigma-Aldrich, Steinheim 
Ethidiumbromide      Roth, Karlsruhe 
Ethylene diaminetetraacetic acid disodium salt  Merck, Darmstadt 
Formamide       Merck, Darmstadt 
Geneticin       Invitrogen, Karlsruhe  
Glutathione       Amersham, Freiburg 
Glycerol       Merck, Darmstadt 
Glycine       Sigma-Aldrich, Steinheim 
Guanidine hydrochloride     Sigma-Aldrich, Steinheim 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid Roth, Karlsruhe 
Igepal CA-630 (NP-40)     Sigma-Aldrich, Steinheim 
Isopropylthio-β-D-galactoside    Serva, Heidelberg 
Iodoacetamide       Bio-Rad, München 
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Imidazole        Fluka, Steinheim 
Leupeptin       Sigma-Aldrich, Steinheim 
Lipopolysaccharide      Sigma-Aldrich, Steinheim 
Magnesium chloride      Merck, Darmstadt 
Magnesium sulfate      Sigma-Aldrich, Steinheim 
Mangan chloride      Merck, Darmstadt 
β-Mercaptoethanol      AppliChem, Darmstadt 
Methanol       Sigma-Aldrich, Steinheim 
MG132 (proteasome inhibitor)    Calbiochem, Germany 
Morpholinoethane sulfonic acid    Serva, Heidelberg 
3-(N-Morpholino)-propanesulfonic acid    Serva, Heidelberg 
Non-fat dry milk      Bio-Rad, München 
Paraformaldehyde      Merck, Darmstadt 
Phenylmethylsulfonyl fluoride    Sigma-Aldrich, Steinheim 
Ponceau S       Roth, Karlsruhe 
Potassium chloride      Merck, Darmstadt 
Rotiphorese Gel 30      Roth, Karlsruhe 
Sodium acetate      Roth, Karlsruhe 
Sodium azide       Merck, Darmstadt 
Sodium chloride      Sigma-Aldrich, Steinheim 
Sodium citrate      Merck, Darmstadt 
Sodium carbonate       Roth, Karlsruhe 
Sodium dodecyl sulfate     Merck, Darmstadt 
Sodium periodate      Sigma-Aldrich, Steinheim 
Sodium thiosulfate       Roth, Karlsruhe 
N,N,N',N’-Tetramethylethylenediamin   Roth, Karlsruhe 
Tris(hydroxymethyl)aminomethane    Roth, Karlsruhe 
Triton X-100       Sigma-Aldrich, Steinheim 
Trypan blue        Gibco, USA 
Tween-20       Roth, Karlsruhe 
Urea        Merck, Darmstadt 
Zeocin        Invitrogen, Karlsruhe  
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3.2. Enzymes 
 
Taq Polymerase      Promega, Mannheim 
T4 DNA Polymerase      Promega, Mannheim 
EcoRI        Promega, Mannheim 
XhoI        Promega, Mannheim 
NdeI        Promega, Mannheim 
BglII        Promega, Mannheim 
HindIII       Promega, Mannheim 
T4 DNA Ligase      Promega, Mannheim 
DNase        Promega, Mannheim 
RNase        Promega, Mannheim 
TEV protease       Invitrogen, Germany 
3.3. Antibodies 
Antibody   Manufacturer    Dilution 
Primary antibodies 
Rabbit α-rat MIF  (Kim, 2003)     1:20,000 
Mouse α-MIF   Picower Institute, Manhasset, NY  1:200 
Mouse α-RP S19  University of Rome, Italy   1:500 
α-GST-HRP   Amersham, Freiberg    1:5,000 
Rabbit α-Jab-1  Santa Cruz, USA    1:500 
α-Biotin-HRP   Amersham, Freiburg    1:1,500 
Mouse α-VCP   ABR, USA     1:1,000 
Rabbit α-VCP   Santa Cruz, USA    1:200 
Goat α-Pgk-1   Santa Cruz, USA    1:200 
Goat α-Fetuin   Santa Cruz,USA    1:200 
Mouse FLAGM2  Sigma, Stenheim    1:10,000 
α –His-HRP   Sigma, Stenheim    1: 8,000 
Mouse α-p-Akt  Cell Signalling, USA    1:1,000 
Rabbit α-Akt   Santa Cruz, USA    1:500 
Rabbit α-Ubiquitin  Santa Cruz, USA    1:500 
Rabbit α-RPN11  Biomol, Hamburg    1:1,000 
Rabbit α-CSN1  Biomol, Hamburg    1:1,000 
Mouse α-Myc (9E10)  Santa Cruz, USA    1:3,000 
Rabbit α-Iкβα   Santa Cruz, USA    1:500 
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Rabbit α-Cullin1  Abcam , UK     1:250 
Rabbit α-Nedd8  Axxora, USA     1:500 
Rabbit α-peroxiredoxin-1 Abcam, UK     1:500 
Secondary antibodies 
Goat α-rabbit-HRP  ICN, Ohio, USA    1:10,000 
Donkey α-rabbit IgG-Cy3 Chemicon, Hampshire, UK   1:1,000 
Donkey α-mouse IgG-FITC Dianova, Hamburg    1:1,000 
Donkey α-goat IgG  Santa Cruz, USA    1:1,000 
Rabbit α-mouse IgG  Cell Signaling , USA    1:100 
3.4. Cells 
 
NIH 3T3 
(mouse fibroblasts) (Research group of Dr.O. Eickelberg, 
  Giessen, Germany) 
 
HEK 293T 
(human epithelial kidney cells) (Research group of Prof. T. Chakraborty, 
Giessen, Germany) 
 
264.7 RAW macrophages 
(mouse macrophage cells)     (Cell Lines Service, Eppelheim, Germany) 
 
HeLa 
(human cervical carcinoma cells) (Research group of Prof. T. Chakraborty, 
Giessen, Germany) 
3.5. Recombinant proteins 
 
Human MIF      produced in own laboratory 
His-VCP      produced in own laboratory 
GST-Jab1/CSN5     produced in own laboratory 
Mouse PDGF      R&D Bioscience, Germany 
Mouse and Human TNFα    eBioscience, Germany 
Ubiquitin chains (Ub2-7), K48-linked  Biomol, Hamburg 
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3.6. Kits 
 
Bradford kit       Roth, GmbH, Karlsruhe 
Gel Extraction Kit      Qiagen, Hilden 
Maxiprep Plasmid Purification Kit    Genomed GmbH, Löhne 
Miniprep Kit       Genomed GmbH, Löhne 
PCR Purification Kit      Qiagen, Hilden 
Silver staining Kit      Invitrogen, Karlsruhe 
QIAX II DNA extraction Kit     Qiagen, Hilden 
FLAG purification Kit     Sigma, Steinheim 
3.7. Cell Culture Media and Antibiotics 
 
Ampicillin sodium salt     Ratiopharm, Ulm 
Kanamycin sodium salt     Ratiopharm, Ulm 
Bovine serum albumin      Invitrogen, Karlsruhe 
Dulbecco’s Minimal Essential Medium   PAA Laboratories, Cölbe 
Fetal calf serum      Invitrogen, Karlsruhe 
L-Glutamine       PAA Laboratories, Cölbe 
MEM Non Essential Amino Acids    PAA Laboratories, Cölbe 
Penicillin/Streptomycin     PAA Laboratories, Cölbe 
RPMI 1640 medium      PAA Laboratories, Cölbe 
Trypsin       PAA Laboratories, Cölbe 
Ultrasaline A       PAA Laboratories, Cölbe 
Optimem-serum free      Invitrogen, Karlsruhe 
3.8. Equipment 
 
Biofuge Fresco      Heraeus, Hanau 
Cell culture incubator      Binder, Tullingen 
Clean bench       BDK, Sonnenbühl-Genkingen 
Confocal laser scanning microscope TCS SP2  Leica, Wetzlar 
Easypet 4420 Pipette      Eppendorf, Hamburg 
Electronic balance SPB50     Ohaus, Giessen 
Gel Jet Imager 2000      Intas, Göttingen 
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Heater Block DB-2A      Techne, Cambridge, UK 
Horizontal Mini Electrophoresis System   PEQLAB, Erlangen 
Microwave oven      Samsung, Schwalbach 
Mini centrifuge Galaxy     VWR International 
Mini-Rocker Shaker MR-1     PEQLAB, Erlangen 
Fluorescence microscope     Carl Zeiss, Jena 
PCR system       Biozyme, Oldendor 
Potter S homogenizer      B. Braun, Melsungen 
Power supply units      Keutz, Reiskirchen 
Pre-Cast Gel System      Invitrogen, Karlsruhe 
SDS gel electrophoresis chambers    Invitrogen, Karlsruhe 
Semi-dry-electroblotter     PEQLAB, Erlangen 
Vertical electrophoresis system    PEQLAB, Erlangen 
Ultrasonic homogenizer     Bandelin, Berlin 
Ultrospec 2100 pro      Biochrom, Cambridge,UK 
2D-PAGE system      BioRad, München 
3.9. Miscellaneous 
 
Bio-Rad Protein Assay     BioRad, München 
Complete Freund's adjuvant     Sigma-Aldrich, Steinheim 
Carrier ampholytes      BioRad, Hercules, CA 
DNA High and Low Mass Ladder    Invitrogen, Karlsruhe 
DNA Ladder (100bp and 1kb)    Promega, Mannheim 
DAPI        Vector, Burlingame,USA 
Enhanced chemiluminescence (ECL) reagents  Amersham, Freiburg, 
Fugene Transfection Reagent    Roche, Mannheim 
Glutathione Sepharose 4B     Amersham, Freiburg 
Hoechst 33342      Sigma-Aldrich, Steinheim 
Hybond ECL nitrocellulose membrane   Amersham, Freiburg 
IPG Strips (11 cm)      BioRad, München 
Lipofectamine 2000      Invitrogen, Carlsbad 
NAPTM-5 Sephadex G-25 column    Amersham, Freiburg 
Ni-Agarose Beads      Novagen, Germany 
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NuPAGE 4-12% Novex Bis-Tris gel    Invitrogen, Karlsruhe 
Protein size markers      Invitrogen, Karlsruhe 
PVDF membrane      Millipor, Germany 
Sterile plastic ware for cell culture    Sarstedt, Nümbrecht 
Streptavidine beads      Novagen, Darmstadt 
SYBR Green I Nucleic Acid Gel Stain   Roche Diagnostics, Mannheim 
Sephacryl S-200 column 10/30 HR column    Pharmacia, Germany 
Transwell filter system     Corning, Schiphol, NL 
X-ray Hyperfilm      Amersham, Freiburg 
3.10. Bacterial strains 
 
E.coli DH5α, E.coli XL1-Blue, E.coli BL21 (DE3) 
3.11. Expression constructs 
 
1. pCMV-MIF (produced in own laboratory) 
2. pN3-CTB-MIF (produced in own laboratory) 
3. pBudCE4.1-birA (produced in own laboratory) 
2. pET28a (+) His-VCP (Dr. P.Colleman, The Babraham Institute, Cambridge) 
3. pFLAG-CMV6-VCP (Prof. M Tagaya, Tokyo University, Japan) 
4. pFLAG-CMV-N (aa 1–198), ND1 (aa 1–470), D1 (aa 199–470), and D2 (aa 471–806) 
domains of VCP (Dr. S. Fang, Maryland University, Biotechnology Institute) 
5. pCIneoJab1/CSN5 (Prof. J. Bernhagen, Univerity of Aachen, Germany) 
6. pcDNA3-Jab1/CSN5 (Prof. J. Bernhagen, Univerity of Aachen, Germany) 
7. pCMV.HA-Ubiquitin (Dr. R. Bohmann, University of Rochester, NY, USA) 
8. pGEX-4T1-Jab1/CSN5 (Prof. J Bernhagen, Univerity of Aachen, Germany) 
9. pcDNA3-HA/Jab1 deletion mutants, 1-110, 110-191, and 1-191 (Prof. S. Jaewhan, 
Sungkyunkwan University, Korea). 
10. pSUPER vector (Prof. M. Eilers , Marburg University, Germany) 
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3.12. siRNAs 
 
1. Negative control (Cat#:AM4621), Applied Biosystems, Darmstadt 
2. VCP (Cat#: AM16708), Applied Biosystems, Darmstadt 
3. Jab1/CSN5 (target sequence: GCUCAGAGUAUCGAUGAAAtt), Applied Biosystems, 
Darmstadt 
4. CSN1 (target sequence: GAACCUUUAACGUGGACAUtt), Applied Biosystems, 
Darmstadt 
5. UPS 15 (target sequence: GCACGUGAUUAUUCCUGUUtt), Applied Biosystems, 
Darmstadt 
3.13. Oligonucleotides cloned into pSUPER vector 
 
 Oligonucleotides were purchased from Sigma (Steinheim, Germany). The 19mer 
target sequences are underlined. Scrambled (scr.) oligonucleotides were cloned to pSuper 
vector as a control. 
Table II: 64mer oliginucleotides cloned to pSUPER vector for MIF, VCP and 
Jab1/CSN5 
 
Name Sequence 
MIF 
forward 5’-GATCCCCCCGCAACTACAGTAAGCTGTTCAAGAGACAGCTTACTGTAGTTGCGGTTTTTGGAAA -3’ 
MIF 
reverse 5’AGCTTTTCCAAAAACCGCAACTACAGTAAGCTGTCTCTTGAACAGCTTACTGTAGTTGCGGGGG-3’ 
MIF 
scr.forward 5’-GATCCCCGCCAACATCGACATATCGGTTCAAGAGACCGATATGTCGATGTTGGCTTTTTGGAAA-3’ 
MIF 
scr.reverse 5’AGCTTTTCCAAAAAGCCAACATCGACATATCGGTCTCTTGAACCGATATGTCGATGTTGGCGGG-3’ 
VCP 
forward 5’-GATCCCCGGGCACATGTGATTGTTATTTCAAGAGAATAACAATCACATGTGCCCTTTTTGGAAA-3’ 
VCP 
reverse 5’AGCTTTTCCAAAAAGGGCACATGTGATTGTTATTCTCTTGAAATAACAATCACATGTGCCCGGG-3’ 
VCP 
scr.forward 5’-GATCCCCGATCGGTATTAGCAGCTAGTTCAAGAGACTAGCTGCTAATACCGATCTTTTTGGAAA-3’ 
VCP 
scr.reverse 5’AGCTTTTCCAAAAAGATCGGTATTAGCAGCTAGTCTCTTGAACTAGCTGCTAATACCGATCGGG-3’ 
Jab1/CSN5 
forward 5’-GATCCCCGCTCAGAGTATCGATGAAATTCAAGAGATTTCATCGATACTCTGAGCTTTTTGGAAA-3’ 
Jab1/CSN5 
reverse 5’AGCTTTTCCAAAAAGCTCAGAGTATCGATGAAATCTCTTGAATTTCATCGATACTCTGAGCGGG-3’ 
Jab1/CSN5 
scr.forward 5’-GATCCCCCGTGACTGAAGATAGACGATTCAAGAGATCGTCTATCTTCAGTCACGTTTTTGGAAA-3’ 
Jab1/CSN5 
scr.reverse 5’AGCTTTTCCAAAAACGTGACTGAAGATAGACGATCTCTTGAATCGTCTATCTTCAGTCACGGGG-3’ 
 Methods 
 
4. METHODS 
4.1. Cell culture techniques 
4.1.1. Cell lines and cell culture 
 
 NIH 3T3 (mouse fibroblasts), HEK 293T (human epithelial kidney cell), 264.7 RAW 
(mouse monocyte-macrophage cell) and HeLa (human cervical carcinoma cell) lines were 
used for the studies. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 
containing 2 mM glutamine supplemented with 10% heat-inactivated fetal calf serum, 100 
U/ml penicillin/streptomycin, 2.7% ultrasaline A and grown in an incubator under 5% CO2 
atmosphere at 37°C. Cells were allowed to grow until 80-90% confluency, washed twice with 
PBS and then splitted at a ratio of up to 1:8 every 2 to 4 days by means of detachment using 1 
ml Trypsin/EDTA (0.5 g/L Trypsin, 0.2 g/L EDTA) per 75 cm2 culture flask. Incubation time 
was 2-3 minutes at 37°C. Trypsin was then inhibited by adding 7 ml DMEM medium 
containing 10% FCS, subsequently cells were collected by centrifugation (500 x g for 10 
minutes at RT). The resulting cell pellet was resuspended in medium and seeded in new 
culture flasks. 
4.1.2. Cell counting and cell viability assessment 
 The trypan blue dye was used to determine the number of viable cells present in a cell 
suspension. Cells were harvested and 20 µl of the cell suspension was mixed with a volume 
(20 µl) of a 0.08% dye solution. The cell suspension was transferred to the edge of the 
hematcytometer and allowed to spread evenly. Viable cells possess intact cell membranes that 
exclude trypan blue and therefore unstained, whereas nonviable cells reveal characteristic 
blue cytoplasm. The cell concentration was calculated as cell number per ml: cell number / 
number of squares x 2 x 104. 
4.1.3. Cell freezing and thawing 
 The cell suspension was diluted 1:1 with freshly prepared freezing medium (70% 
DMEM, 10% FCS and 20% DMSO). For freezing, cells were first incubated at -80ºC 
overnight and then store in liquid nitrogen. To thaw the cells, a vial was transfered to an 
incubator (37ºC) for 2 minutes and then plated directly with the fresh medium.  
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4.1.4. Transfection 
 Transfection means the introduction of foreign material into eukaryotic cells. It 
typically involves the opening of transient pores or 'holes' in the cell plasma membrane to 
allow the uptake of molecules, such as supercoiled plasmid DNA or siRNA constructs. In this 
study, three transfection types were used as described below. 
4.1.4.1. Transient transfection 
 
 Cells were seeded in 6-well plates one day before transfection at a density of 2 x 105 
cells and transiently transfected with 1 µg of expression plasmid using FuGene 6 (Roche) 
according to the product manual. 0.5 µg of DNA per construct in double tranfections and 0.33 
µg of DNA per construct in triple transfections were used. Total DNA/well was kept constant 
at 1 µg. 24h after transfection gene expression was assayed by immunoblotting. 
4.1.4.2. Stable transfection 
  
For stable transfection pBudCE4.1-birA and pN3-CTB-MIF were linearized with Xho 
I and EcoRI, respectively, and transfected, alone or combined (pBudCE4.1-birA) into NIH 
3T3 cells using Lipofectamine (Invitrogen) following the manufacturer’s instructions. 
Antibiotic selection started with 800 µg/ml Geneticin (for pN3-CTB-MIF) and 600 µg/ml 
Zeocin (for pBudCE4.1-birA) and was gradually reduced in three steps after 4 weeks up to 
100 µg/ml Geneticin and 150 µg/ml Zeocin. Clones were checked by immunobloting with 
rabbit anti-rat-MIF antiserum and streptavidin HRP conjugate for expression of a biotinylated 
22 kDa MIF fusion protein. After five to eight weeks clones were isolated using small sterile 
filter discs soaked in trypsin solution. The highest efficiency of biotinylation was achieved 
with the addition of 0.1 mg/ml of biotin to the medium.One clone with strong expression of 
the MIF fusion protein and one control clone expressing birA only were cultured in DMEM 
supplemented with 10% FCS, biotin (0.1 mg/L), Geniticin (100 µg/ml) and Zeocin (150 
µg/ml) at 37°C. 
4.1.4.3. siRNA transfection 
  
 For transient knockdown, cells were seeded in 6-well plates at 30-50 % confluency 
24h before siRNA tranfection. Immediately before transfection, cells were washed twice and 
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then resuspended in OptiMEM serum free medium (Invitrogen). Transfection of siRNA (100 
pmol final concentration) was performed in Opti-MEM medium according to the 
manufacturer’s protocol (Lipofectamine 2000, using 4µl transfection reagent/100 pmol 
siRNA). After 6h transfection, medium was replaced 6h later with serum containing DMEM 
and cell culture was continued for 72h. 
4.1.5. Stimulation of cells with activators and inhibitors 
  
 TNF-α (10-100 ng/ml), LPS (10-100 ng/ml), MIF (50-100 ng/ml) and PDGF (10-50 
ng/ml) were used for stimulation of cells and incubated for certain time points starting from 5 
min to 1h. MG132 (50 µM) was used for 1h to block to proteasome activity.  
4.1.6. AKT activation assays 
  
 1 x 106 NIH 3T3 fibroblasts were seeded in 24-well plates and incubated in DMEM 
medium containing 10% FCS for 24h. Medium was changed and cells were cultured in 
DMEM containing 0.5% FCS for 24h. rMIF in 20 mM sodium phosphate buffer, pH 7.2, was 
added to the cells at a final concentration of 50 ng/ml. As a negative control, cells were 
incubated with buffer, obtained from a batch of the final dialysis refolding buffer. As a 
positive control PDGF (20 ng/ml) was used. All additions were performed within the 
incubator to minimize temperature changes and all reagents added were pre-warmed. 
Incubations were stopped at the indicated times (0–60 min) by washing the cells twice with 
cold PBS. Then, cells were lysed with lysis buffer (PBS, pH 7.4, containing 1% NP-40, 0.5% 
sodium deoxycholate, 1 mM EDTA, 1 x proteinase inhibitor cocktail and 1 mM sodium 
orthovanadate). Cell lysates were prepared as described in section 4.2.1. 
4.2. Protein-biochemical methods 
4.2.1. Cell lysate preparation 
 
 Cells were grown in a 75 cm2 culture flaks to 80% confluency, washed twice with ice-
cold PBS and incubated on ice with 1 ml of lysis buffer (50 mM Tris-Cl pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 1% NP-40, 1 µM leupeptin, 1 mM PMSF) for 15 min with occasional 
rocking. Cells were scraped out, transferred to an Eppendorf tube and disrupted by passage 
through a 21 Gauge needle, subjected to sonication (two 10 sec bursts at 200-300 W with a 10 
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sec cooling period in between) followed by centrifugation at 13,000 x g for 10 min at 4°C. 
4.2.2. Protein concentration measurement (Bradford, 1976) 
 
 The Bradford dye assay was used to determine the concentration of proteins in a 
solution. The assay reagent was prepared by diluting 1 volume of the dye stock (Protein 
Assay, BioRad) with 4 volumes of distilled H2O. The solution appears brown, and has a pH of 
1.1. Bovine serum albumin (BSA) at concentrations of 0, 250, 500, 1000, 1500, 2000 µg/ml 
were used as standards. Both the standards and the samples were prepared in PBS and 1ml 
assay reagent was mixed with 20 µl sample or standard. After 5 min incubation time they 
were measured at 595 nm absorbance in a spectrophotometer. 
4.2.3. Affinity purification  
4.2.3.1. Purification and elution of biotin tagged protein  
 
  Biotinylated MIF (biotin.MIF) and associated components were purified from the 
NIH 3T3 cell lysate by affinity selection on a streptavidin agarose matrix. Cytoplasmic 
extracts (prepared as described in 4.2.1) from cells expressing biotin.MIF and biotin ligase 
birA or birA only were incubated with 50 µl streptavidin-agarose beads (Novagen) for 1.5h at 
room temperature by rotating wheel. Following incubation, beads were washed three times 
with lysis buffer. Between washing steps, beads were pelleted by centrifugation and bound 
proteins were eluted by boiling for 10 min in 1 x SDS sample buffer (62.5 mM Tris pH 6.8, 
2% SDS, 5% glycerol, 0.3% bromophenol blue, 0.9% (v/v) β-mercaptoethanol), separated on 
a 4-12 % NuPAGE Bis-Tris gel (Invitrogen).  
4.2.3.2. TEV-protease digestion on strepavidin beads 
 
  In order to remove the biotin tag from Biotin.MIF, proteins were eluted from the 
streptavidin beads by incubation with Tobacco Etch Virus (TEV) protease that recognizes the 
seven specific amino acid sequences Glu-X-X-Tyr-X-Gln-Ser. Following affinity purification 
with streptavidin beads, 150 µl TEV digestion buffer (Invitrogen, prepared according to the 
manufacturer protocol) was incubated with beads for 1h at 30°C by rotation. Following TEV 
digestion, beads were collected by centrifugation and the supernatant containing cleaved MIF 
and potential MIF partners was transferred to a new Eppendorf tube. To increase the protein 
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concentration, TEV eluates from 3 experiments were combined and protein from 450 µl 
eluate was precipitated with cold acetone (four times sample volume) overnight at -20ºC. 
Precipitated proteins were separated by 1D- and 2D-SDS-PAGE analysis. 
4.2.4. 1D-SDS polyacrylamide gel electrophoresis 
Discontinuous sodium-dodecyl-sulphate (SDS) polyacrylamide gel electrophoresis 
(Laemmli 1970) was performed to analyze protein expression in cell lysates. An 18% 
resolving gel solution (375 mM Tris-HCl pH 8.8, 0.1% SDS, 18% acrylamide, 0.05% APS, 
0.05% TEMED) was poured into the assembled gel mold between two glass plates separated 
by 1 mm thick spacers leaving about 1 cm space for the stacking gel solution (125 mM Tris-
HCl pH 6.8, 0.1% SDS, 4% acrylamide, 0.05% APS, 0.1% TEMED). Samples were prepared 
in l x SDS gel sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 5% glycerol, 0.3% 
bromophenol blue, 0.9% (v/v) β-mercaptoethanol) and boiled for 5 min to denature the 
proteins. After polymerization of the stacking gel, the comb was removed and the gel 
mounted in the electrophoresis chamber. Electrode reservoirs were filled with 1x SDS 
electrophoresis buffer (25 mM Tris, 1.44% glycine, 0.1% SDS), the wells were cleaned and 
samples loaded. Electrophoresis was performed at 150 V constant. For immunoprecipitation, 
samples NuPAGE 4-12% precast gradient-gels were used, which were run in 1x MES buffer 
(50 mM MES, 50 mM Tris, 3.46 mM SDS, 1.025 mM EDTA) or 1x MOPS (50 mM MOPS, 
50 mM Tris, 3.46 mM SDS, 1.025 mM EDTA ) at constant 200 V for 1h.  
4.2.5. 2D-SDS polyacrylamide gel electrophoresis 
 
 Proteins were resuspended in 130 µl of isoelectric focusing (IEF) sample rehydration 
buffer (8 M urea, 50 mM DTT, 4% CHAPS, 0.2% carrier ampholytes, 0.0002% Bromophenol 
Blue) at room tempature. After placing samples in a rehydration tray, linear strips (IPG Strips, 
BioRad) were placed face down in a tray containing sample rehydration buffer. IEF strip 
rehyration was maintained at room temperature overnight. IEF was performed for a total of 
10.000 Volt-hours with the voltage conditions: 250 V for 15 min, ramping to 4000 V over 2h 
and maintenance at 4000 V for about 3h. Prior to running the second dimension, the IEF strips 
were equilibrated for 15 min in fresh equilibration buffer 1 (6 M urea, 20% glycerol, 2% SDS, 
0.375 M Tris-HCl pH 8.8, 130 mM DTT). For another 15 min, equilibration was performed in 
equilibration buffer 2 (6 M urea, 20% glycerol, 2% SDS, 0.375 M Tris-HCl pH 8.8, 135 mM 
iodoacetamide). The IEF strips were washed twice with 1x SDS electrophoresis buffer (see 
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4.2.4), placed on 12.5% SDS gel and sealed with a 3% agarose solution. Vertical second 
dimension was run at 160 V for 45 min.  
4.2.6. Immunoblotting 
Proteins were separated on 10-18% SDS-PAGE gel and electro-transferred to a 
nitrocellulose membrane at 100 mA per gel/membrane for 90 min using a semi-dry blot 
system. After blotting, the membrane was incubated in blocking buffer (5% (w/v) non-fat dry 
milk in PBS containing 0.1% Tween-20) for 1h at RT. Subsequently, the membrane was 
incubated overnight at RT or 4°C with the first antibody diluted in blocking buffer or as stated 
in the text. After washing (3 x 10 min) with PBS-Tween, the membrane was incubated for 1h 
at RT with a secondary antibody diluted in blocking buffer. Three washing steps (10 min 
each) with PBS-Tween were performed before the membrane was incubated with ECL 
Detection Reagent (1:1 mixture (v/v) of Reagent 1 and Reagent 2) for 60 sec. The membrane 
was wrapped in plastic foil, exposed to X-ray film for 1-15 min, which was subsequently 
developed.  
4.2.7. SDS Gel Staining and protein analysis by MALDI 
4.2.7.1. Silver staining  
 
 Proteins separated on 1D- and 2D-SDS polyacrylamide gel electrophoresis were 
subsequently silver stained as described previously with minor modifications (Blum et al., 
1987). Gels were placed in a fixation solution (50% methanol, 10% acetic acid) for 1h and 
washed with 30% ethanol for 30 min to remove the acetic acid. Gels were then sensitized for 
1 min with 0.02% sodium thiosulfate and rinsed three times with deionized water followed by 
incubation in silver staining solution (0.2% silver nitrate, 0.075% formaldehyde) for 30 min. 
Gels were then transferred into a new clean tray, rinsed twice with deionized water and placed 
in developing solution (6% sodium carbonate, 0.03% formaldehyde, 2% sodium thiosulfate 
from sensitizing solution) until protein spots were clearly visible. The development reaction 
was terminated by replacement of the developing solution with a stop solution (fixing 
solution) for 15 min. Stained gels were rinsed twice with deionized water for 15 min to 
remove remaining fixing solution and placed in a preserving solution (30% ethanol, 5% 
glycerol) for 2 h. For longer storage, gels were air-dried for 3 days using Gel Air Dryer 
(Sigma) with a cellophane support. 
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4.2.7.2. Coomassie blue staining  
After electrophoresis gels were incubated in fixing solution (7% glacial acetic acid in 
40% (v/v) methanol) for 1h. Staining solution was prepared by mixing 4 parts of 1x Brilliant 
Blue G-Colloidal with 1 part methanol and the gel was incubated overnight with gentle 
shaking. The gel was then rinsed for 60 sec with destaining solution I (10% acetic acid in 25% 
(v/v) methanol) to reduce the background staining, followed by destaining solution II (25% 
methanol) until a sufficient destaining level was reached. For documentation purposes the gel 
was scanned and dried between cellophane on air. 
4.2.7.3. Image and protein analysis (MALDI) 
 
 After performing Coomassie and Silver staining, lanes from 1D-SDS-PAGE and spots 
from 2D-SDS-PAGE were cut into slices and proteins in all slices were digested with trypsin 
separately (Shevchenko et al., 1996). Extracted peptides were separated and sequenced by 
LC-coupled ESI-tandem MS on a Q-TOF instrument (Q-TOF ultima, Waters) under standard 
conditions. Proteins are identified by searching peptide fragment spectra against all entries in 
the NCBI database using MASCOT as search engine. 
4.2.8. Co-immunoprecipitation 
Cells were washed once in ice cold PBS and then lysed in 500 µl RIPA buffer 
containing proteinase inhibitors (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10 
mM K2HPO4, 10% v/v glycerol, 1% NP–40, 0.15% SDS, 1 mM Na3VO4, 1 mM sodium 
molybdate, 20 mM NaF, 0.1 mM PMSF). Cells were disrupted by passing the cell suspension 
through 21-gauge needles and then centrifuged at 13,000 x g for 10 min at 4°C. After 
clearance of lysate, supernatants (500µl) were diluted (1:2) with IP (immunoprecipitation) 
buffer [20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 20 mM NaF, 
protease inhibitor cocktail (Sigma)] and incubated on a permanent rotator (10 r.p.m.) at 4°C 
for 3h to overnight with 30 µl Protein G-Sepharose 4B Fast Flow beads (Amersham) 
preloaded with respective antibodies (1-2 µg). Afterwards, the beads were washed three times 
with 1 ml ice-cold IP buffer. After complete removal of the buffer, immune complexes were 
collected by centrifugation, resuspended in 25 µl of 3x SDS–PAGE sample buffer and boiled 
for 10 min at 95°C. The IP samples were separated on a NuPAGE 4-12% Novex Bis-Tris gel 
(Invitrogen) and either blotted to Nitrocellulose membranes (Amersham) or stained with 
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colloidal Coomassie staining solution. 
4.2.9. Expression and purification of recombinant GST-Jab1/CSN5 and His-VCP 
 
 Jab1/CSN5 was expressed as a fusion protein with GST tag and VCP was expressed as 
a fusion protein with His tag. For expression of GST-Jab1/CSN5 or His-VCP, E. coli BL21 
DE3 competent cells were transformed with the pET28a (+) His-VCP or pGEX-4T1-
Jab1/CSN5 constructs (bacterial transformation described in section 4.3.1). Positive 
transformants were inoculated in to 5 ml 2YT medium (1.6% tryptone, 1% yeast extract and 
1% NaCl, pH 7.0) containing antibiotics (kanamycin for His-VCP, ampicillin for GST-
Jab1/CSN5) and cultured overnight in a shaker at 37°C.  
 To optimize expression conditions, 50 ml of 2YT medium (2% (w/v) bactotryptone, 1 
% (w/v) yeast extract, 100 mM NaCl, pH 7.0) containing 50 µg/ml antibiotics (kanamycin or 
ampicillin) was inoculated with 500 µl of overnight culture. Cultures were kept at 37°C in a 
shaking incubator until OD600 = 0.5. The culture was split in two equal parts and 1 ml aliquot 
from each culture was saved and prepared for SDS-PAGE. One culture was induced by 
adding IPTG to a final concentration of 0.5 mM and incubation was continued at 37° with 
shaking. At different time points of induction (1, 2 and 3h), 1 ml from each culture were 
transferred to a microfuge tube, the OD600 was measured and each pellet was prepared for 
SDS-PAGE. The samples were mixed with 1x SDS sample buffer, boiled at 95°C for 3 min, 
stored on ice and then loaded onto 12.5 % SDS-PAGE. The gel was stained with Coomassie.  
For large scale expression 5 ml of an overnight culture was inoculated into 400 ml 
2YT medium (supplemented with 100 µg/ml ampicillin or kanamycin) and incubated at 37°C 
until an OD600 of 0.5 was reached. Expression was induced by adding IPTG to a final 
concentration of 0.5 mM and incubation was continued at 37°C for 3h. Cells were harvested 
by centrifugation at 3,000 x g at 4°C for 30 min. The supernatant was discarded and the cell 
pellet was resuspended in ice-cold PBS (50 µl PBS for each ml of culture). The cells were 
lysed by sonication (10 short burst of 10 sec followed by intervals of 30 sec for cooling) and a 
small aliquot was saved after this step. Cell lysates were treated with Triton X-100 to a final 
concentration of 1% and gently mixed for 30 min to solubilize the fusion protein. 
Centrifugation at 1200 x g for 10 min at 4°C removed the cell debris and the supernatant was 
transferred to a new tube. An aliquot of supernatant and pellet was saved for analysis by SDS-
PAGE to identify the fraction that contains the fusion protein.  
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Supernatant contained His-VCP or GST-Jab1/CSN5 were further resuspended in lysis 
buffer (50 mM Tris-HCl, 1mM EDTA, 100 mM NaCl, pH 8.0), treated with 1mg/ml 
lysozyme and DNAase I for 30 min on ice. Lysed cells were centrifuged at 14,000 x g for 15 
min at 4°C and the pellet containing mainly inclusion bodies was washed four times with lysis 
buffer. The resuspended inclusion body pellet was incubated with denaturation buffer (6 M 
guanidium hydrochloride, 10 mM DTT in PBS) at room temperature on a rotating plate for 30 
min and centrifuged at 4°C at 12.000 rpm for 15 min. After incubation with denaturation 
buffer, the cleared lysate was dialyzed against PBS pH 7.8 containing 0.5 mM PMSF and 1 
mM DTT for 4h. After dialysis, the cleared cell lysate incubated with 50% Ni-NTA slurry (1 
ml bed volume for 10 ml lysate) at 4°C for 60 min. The matrix was then washed twice with 50 
mM NaH2PO4 pH 8.0, 300 mM NaCl, and 20 mM imidazole. Bound protein was eluted with 
50 mM Na2HPO4, 300 mM NaCl, 250 mM imidazole, pH 8.0 and dialyzed against PBS pH 
7.8 containing 0.5 mM PMSF and 1 mM DTT. The purity of the eluted protein was estimated 
by SDS-PAGE. 
 For the purification of GST-Jab1/CSN5, supernatant containing GST-Jab1/CSN5 was 
subjected to Glutathion Sepharose 4B chromatography at 4°C 2h. The matrix was washed 
twice with 5 bed volumes of PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4) and bound proteins were eluted with 10 mM Glutathione in 50 mM Tris-HCl pH 
8.0 (GST-Jab1/CSN5 was purified by Suada Fröhlich and Dr. Jörg Klug). 
4.2.10. In vitro pull-down assays 
4.2.10.1. His-VCP pull-down 
 
His-VCP (1 µg) was immobilized with 30 µl (50% slurry) of Ni-NTA beads by 
incubation at RT on a rotating wheel for 1h. In order to remove the unbound protein, beads 
were washed 3 x with PBS. Coated beads were incubated for 2h with increasing amounts of 
recombinant GST-Jab1/CSN5 (0.5, 1 and 2 µg respectively) on a rotating wheel for 2 h at 4°C 
in binding buffer containing 25 mM Tris-HCl pH 8.0, 200 mM KCl, 2 mM MgCl2, 1 mM 
ATP, 1 mM dithiothreitol, 5% glycerol and 1% Triton X–100. As a control, uncoated Ni-NTA 
beads were incubated with 2 µg GST-Jab1/CSN5. After extensive washing with binding 
buffer, the beads were boiled in SDS sample buffer for 5 min. Proteins were resolved on SDS-
PAGE and either stained with colloidal Coomassie or detected by immunoblotting.  
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4.2.10.2. GST-Jab1/CSN5 pull-down 
 
 1 µg of GST-Jab1/CSN5 was immobilized with 30 µl (50% slurry) of glutathione 
sepharose beads by incubation 500 µl PBS at RT on a rotating wheel for 1h. After 3x washing 
with PBS, beads were incubated with His-tagged VCP protein (0.5, 1 and 2 µg respectively) 
for 2h at 4°C in binding buffer (same as 4.2.11.1) on a rotating wheel for 2h at 4°C. As a 
control, His-VCP was incubated with uncoated glutathione beads. After extensive washing 
with binding buffer, GST-Jab1/CSN5 bound proteins were analyzed by immunoblotting.  
 For ubiquitin binding, GST-Jab1/CSN5 bound to glutathione sepharose beads was 
incubated with polyubiquitin chains (Ub2–7) in binding buffer (50 mM HEPES, pH 7.5, 150 
mM NaCl, 5 mM EDTA, 1% Triton X) for 3h at 4°C. The beads were washed 3x with 
binding buffer and then boiled in SDS sample buffer for 5 min. Bound material was separated 
on SDS-PAGE, transferred to nitrocellulose membrane and subjected to immunoblotting. 
4.3. Molecular biology methods 
4.3.1. Preparation of competent E. coli and transformation 
 
For the preparation of competent E. coli an inoculating loop was used to streak E. coli 
DH5α directly from a frozen glycerol stock onto an LB agar plate containing no antibiotics. 
The plate was incubated for 16h at 37°C. A single colony was picked and grown in 5 ml SOB 
medium overnight by shaking (235 rpm/min) at 37°C. 50 ml pre-warmed SOB medium (2% 
(w/v) bactotryptone or peptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl) was 
inoculated with 0.5 ml from the overnight culture. The cells were grown for 2.5-3.0 h at 37°C 
under monitoring culture growth by measuring OD600 in a spectrophotometer every 20 min. 
When the culture had reached an OD of 0.45-0.50, the cells was incubated on ice for 20 min. 
Cells were harvested by centrifugation at 1075 x g for 15 min at 4°C and the supernatant was 
decanted. The cells were gently resuspended in 100 ml TFB buffer (10 mM MES, 45 mM 
MnCl2, 10 mM CaCl2, 100 mM KCl, pH 6.2) and incubated on ice for 10-15 min. After 
centrifugation at 1075 x g for 15 min at 4°C, the buffer was decanted. The cells were 
resuspended gently in 3.9 ml TFB buffer, 140 µl DMSO followed by 5 min incubation on ice. 
Then 140 µl of 1M DTT was added and incubation continued for 10 min before another 140 
µl DMSO were added for 5 min. For transformation, 200 µl of competent cells were 
transferred to an Eppendorf tube and kept on ice. 3 to 7 µl of ligation reaction mixture 
containing 50 ng of plasmid were added to the competent cells and incubated on ice for 30 
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min. The tubes were transferred to a heat block preheated to 42°C for exactly 45 sec and then 
cooled on ice again. After 2 min of cooling 800 µl of warm (37°C) SOC medium (SOB 
medium containing 5 mM glucose) was added to each tube. Incubation for 60 min in a 
shaking incubator allowed the bacteria to recover and to establish antibiotic resistance. 200 µl 
of transformed compotent cells were plated onto 90 mm LB agar plates containing the 
appropriate antibiotic (50 µg/ml). The plates were stored at RT until the liquid had been 
absorbed. The plates were inverted and incubated at 37°C overnight. One colony was picked 
and inoculated in 5ml mini culture (SOB medium containing antibiotic).  
4.3.2. Plasmid DNA isolation (mini and maxi bacterial culture preparation) 
 
One colony was picked and used for inoculation of a 5 ml mini culture (SOB medium 
containing antibiotic). The bacterial culture was incubated overnight at 37°C in a shaking 
incubator. The Promega Minipreps DNA Purification Kit was used for the plasmid DNA 
isolation according to the manufacturer’s recommendation. The standard method for the 
maxiprep isolation of plasmid DNA includes the same general strategy as the mini scale 
isolation. However, 200 ml medium containing antibiotic inoculated with plasmid-containing 
colonies are incubated in a 37°C shaker for 12-16h. Isolated plasmid DNA was subjected to 
agarose gel electrophoresis. 
4.3.3. Agarose gel electrophoresis 
Agarose gels (0.8% to 1%) were routinely used to separate DNA fragments ranging in 
size from 100 bp to 10 kb. The appropriate amount of agarose was dissolved in 1x TAE buffer 
(40 mM Tris-acetate, 1 mM EDTA pH 8.0) by heating in a microwave oven. After cooling the 
gel solution was poured into a gel mold, a comb was inserted in order to generate wells for the 
samples. After 30-40 min the comb was removed, and the gel mounted into an electrophoresis 
chamber filled with 1x TAE buffer. DNA samples and size marker were mixed with an 
appropriate volume of DNA sample buffer (3% glycerol, 0.025% bromophenol blue, 0.025% 
xylene cyanol FF) and pipetted into the wells. The gels were run at 100V (2-10V/cm gel) until 
the bromophenol blue and xylene cyanol dyes had migrated considerable distance through the 
gel. After electrophoresis, the gel was immersed in 1x SYBR green staining solution 
(1:10,000 in 1x TAE buffer) and incubated for 30 min at RT with gentle shaking. 
Occasionally, SYBR green staining solution was added directly to the sample. The gel was 
then examined on a 305 nm UV transilluminator and photographed using a gel documentation 
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system.  
4.3.4. Cloning of pN3-CTB-MIF 
 
The MIF cDNA was produced by standard PCR (annealing temperature 52°C for 5 
cycles and 56°C for 30 cycles) using the upstream primer 
CGAATTCCGCCACCATGCCTATGTTCATCGTG (Eco RI site in bold) and the 
downstream primer GATGTCGACAGCGAAGGTGGAACCGTTCCA (Sal I site in bold) 
and a pGEX-4T-2 MIF full length expression construct (unpublished) as template. The 
method of de Boer et al. (de Boer et al., 2003) was employed using the modified tagging 
construct pN3-CTB developed by Rischitor et al. (Rischitor, 2005). pN3-CTB-MIF was 
constructed by ligating the Eco RI/Sal I restricted PCR fragment into pN3-CTB opened with 
Eco RI and Sal I (pN3-CTB-MIF was cloned by Tamara Henke and Dr.Jörg Klug). 
4.3.5. Cloning of inserts into the shRNA vector pSUPER 
 
 For the knockdown of MIF the shRNA vector pSUPER was used (Brummelkamp et 
al., 2002). It is based on the RNA polymerase III H1 RNA-gene promoter that is directing the 
expression of a short hairpin RNA. This shRNA is cleaved by the nuclear RNase Drosha, 
processed by the cytoplasmic RNase Dicer and eventually incorporated into the RNA-induced 
silencing complex RISC that is effecting gene specific silencing. The shRNA is defined by 
cloning a short insert obtained by annealing a pair of custom 64mer oligonucleotides (Sigma) 
that contains a unique 19-nt sequence derived from the MIF mRNA followed by a 9 bp spacer 
encoding the RNA hairpin and the reverse complement of the same 19-nt sequence (see 
Figure 6). 
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Figure 6: Strategy for cloning the MIF-specific pSUPER vector. 
 
For an experiment utilizing a pSUPER vector general steps were followed as outlined below. 
• Annealing of upper and lower strand of the insert  
• Linearization of the pSUPER vector with Bgl II and Hind III  
• Cloning of annealed oligos into the vector 
• Transformation into bacteria, selection of insert containing clones, verification of the 
insert sequence by DNA sequencing using the T7 promoter primer (Seqlab, Göttingen) 
and purification of plasmid DNA suitable for transfections 
• High efficinecy transfection of pSUPER-MIF into mammalian cells 
• Assaying the knock-down effect on protein expression and/or mRNA level 
4.3.5.1. Annealing of oligos 
 
 The 64mer oligonucleotides were obtained from Sigma and dissolved in Tris-EDTA, 
pH 8.0 at 100 pmol/µl. 20 µl of each oligonucleotide (approx. 20 µg), 10 µl 10x annealing 
buffer (100 mM Tris-HCl pH8.0, 10 mM EDTA, 300 mM KCl) and 50 µl water were mixed 
in a reaction tube. Ample Water was heated in a 500 ml beaker to boiling point, taken off the 
heat source, and the reaction tube was incubated in the hot water with the aid of a floatable 
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tube holder. When the water in the beaker had cooled down to room temperature dilutions of 
the annealed oligonucleotides were made (40 ng/µl and 4 ng/µl) and stored together with the 
stock solution at -20°C. 
4.3.5.2. Ligation into pSUPER 
 
 20 µg pSUPER vector were digested with Hind III and Bgl II. The linearized vector 
was purified over a 1% agarose gel and extracted using a DNA gel purification kit. The 
ligation reaction was set up by mixing 1 µl pSuper (approx. 100 ng/µl), 2 μl of the annealed 
oligos (approx. 4 ng/µl), 5 μl of 2x T4 DNA ligase buffer, 1 μl H2O and 1 μl T4 DNA ligase. 
Cloning controls included a ligation reaction without insert and a reaction without insert and 
ligase. Half of the ligation reaction was used to transform competent E. coli DH5α (see 
section 4.3.1). 5 ng of a standard plasmid vector were used as a transformation control.  
 Bacteria were plated on ampicillin-agar plates and grown overnight. Colonies were 
picked and grown overnight in ampicilin containing LB medium. Clones were checked by 
digestion with Bgl II (the Bgl II site is destroyed in positive clones) (Figure 7, lane 4-7). One 
or two positive clones confirmed by DNA sequencing (Seqlab, Göttingen). 
 
 
 
Figure 7: Determination of positive clones digested with Bgl II 
Lane 1: 1kb marker; Lane 2: pSUPER vector; Lane 3: pSuper vector digested with Bgl II; 
Lane 4-5; Lane 6-7: positive clones uncut by Bgl II; and Lane 8-9: negative clone were shown 
on 1% agarose gel.   
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4.3.5.3. Transfection of mammalian cells 
 
 One day before transfection, cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum so that they reached 50-70% 
confluence at the time of transfection. Transient transfection was performed with 
Lipofectamine 2000 (Invitrogen) according to the prodecure recommended by the supplier. 
The level of suppression of our target gene was measured by immunoblotting (Figure 8). 
 
 
Figure 8: Knockdown of MIF in 264.7 RAW macrophages and NIH 3T3 cells. 
264.7 RAW macrophages and NIH 3T3 cells were transfected with either pSUPER vector 
(lane 1) or MIFsi (lane 2 and 3) for 48 hours. Cytoplasmic fractions were analyzed by 
Western blotting. The blot was stripped and reprobed with β-actin antibody as a loading 
control. 
4.4. Gel filtration assay 
 
 HEK 293T lysates (containing 3 mg of protein) were separated by gel filtration 
chromatography using a Sephacryl S-200 column 10/30 HR column (Pharmacia) in a buffer 
containing 25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1 mM 
ATP and 10% glycerol. One-milliliter fractions were collected, 300µl was precipitated with 
acetone, resolved in SDS containing sample buffer and examined by SDS-PAGE. 
4.5. Double immunofluorescence 
 
Immunofluorescence staining was performed on NIH 3T3 mouse fibroblasts to 
investigate the cellular localization of endogenous MIF and its associated proteins. Cells were 
cultured on cover slips until 80% confluency. After washing once with 1x PBS, cells were 
fixed with ice-cold methanol for 10 min at RT. Blocking was performed with 5% BSA and 
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10% NHS for 1h at RT. Double immunostaining with rabbit anti-VCP (1:400), rabbit anti-
Pgk-1, rabbit anti-RPS 19, followed by donkey anti-rabbit IgG conjugated with Cy3 
(1:1,000), and mouse anti-MIF (1:200) followed by donkey anti-mouse IgG conjugated with 
FITC (1:1,000) was performed. Primary antibodies were incubated over night at 4°C and 
secondary antibodies were incubated for 1h at RT. After incubating with primary and 
secondary antibodies, three wash steps were performed using 1x PBS. Images were acquired 
with a confocal laser scanning microscope. 
4.6. FRET (Fluorescence Resonance Energy Transfer) 
 
FRET was combined with CLSM (confocal laser scanning microscopy) and double-
labeling indirect immunofluorescence to identify associations of proteins. Cells were cultured 
on the 24-well slides and transfected with different plasmids using the same transfection 
procedure as described above. Twenty-four hours after transfection, cells were fixed with 4% 
PFA for 15 min. Jab1/CSN5 and VCP were labeled using conventional indirect double-
labeling immunofluorescence technique (anti-Jab1/CSN5 from rabbit labeled with Cy5-
conjugated secondary reagent, anti-VCP antibody labeled with Cy3- conjugated secondary 
reagent). Both primary antibodies were applied simultaneously and incubated overnight at 
4oC. After a washing step, Cy3-conjugated donkey anti-mouse-Ig was applied for 1h and after 
a second washing step the cells were incubated with Cy5-conjugated F(ab')2 donkey anti-
rabbit-Ig. For control of the species-specificity of the secondary reagents, only the anti-
Jab1/CSN5 antibody and both secondary antibodies were applied. FRET was quantified by 
the acceptor photobleaching method using a CLSM. FRET was quantified by measurement of 
the fluorescence intensity in the Cy3 (donor) channel in the bleached area before and after 
bleaching. Cy5 (acceptor) was bleached 5 times (1.28 s/scan) with highest possible zoom 
(X32) with 100% laser power of the 633 nm HeNe laser line. To assess changes during the 
measurements that were not due to FRET, four rectangular region of interest (ROI) of 
approximately the same size as the bleached area were measured adjacent to the bleached 
area. The CLSM settings were as follows: Detection of Cy3: 52% laser power at 543 nm, 
detection at 555–620 nm; Cy5: 20% laser power at 633 nm, detection at 639–738 nm. FRET 
efficiency was shown as change of fluorescence intensity (absolute increase in fluorescence 
(ΔIF)=IDA-IDB, where IDA is the donor intensity after bleaching and IDB the donor intensity 
before bleaching. 
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Differences among experimental group and control group in the FRET-experiments 
were analyzed with the Kruskal-Wallis test followed by the Mann-Whitney test using SPSS 
software, version 12 (SPSS GmbH Software, Munich, Germany), with p ≤ 0.05 being 
considered as significant and p ≤ 0.01 as highly significant. 
                Results 
5. RESULTS  
5.1. Identification of MIF interacting proteins 
 
 In order to identify new MIF interacting proteins, the following strategy was implied. 
Initially, a recently developed in vivo biotin tagging method followed by affinity based 
chromatography methodologies was applied for purification of new MIF interacting proteins. 
Subsequently, these proteins were identified by MALDI-TOF mass spectrometry. Finally, the 
putative interaction between MIF and associated proteins were confirmed by Fluorescence 
Resonance Energy Transfer (FRET), co-immunoprecipitation and in vitro pull-down 
experiments.  
5.1.1. In vivo biotinylation of MIF 
 
 In vivo biotinylation of MIF was conducted by stable cotransfection of pN3-CTB-MIF 
and BirA enzyme expression vector pBudCE4.1-birA into NIH 3T3 cells. The principle of the 
specific in vivo biotinylation of MIF in NIH 3T3 cells is shown in Figure 9.  
 
 
 
Figure 9: Principle of the in vivo biotinylation of MIF stably expressed in NIH 3T3 cells.  
The MIF backbone is shown together with bound hypothetical interaction partners P1, P2, P3 
etc. The tag contains a calmodulin binding peptide (CBP), a TEV protease cleavage site and a 
biotinylation tag. The bacterial biotin ligase birA required for biotinylation of the tag is stably 
co-expressed in the same NIH 3T3 clone.  
 
The efficiency of biotinylation of the MIF target protein by stable coexpression of the 
BirA enzyme in vivo was evaluated by SDS-PAGE analysis (Figure 10). Protein extracts from 
cells expressing tagged MIF and BirA (double transfectant) or BirA only (single transfectant) 
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were applied to 18% SDS gel, transferred to nitrocellulose membranes and probed with anti-
MIF antibody (Figure 10, upper panel) to detect endogenous and biotinylated MIF 
(biotin.MIF). The same membrane was then stripped and reprobed with streptavidin-HRP 
(Figure 10, lower panel) to detect biotin.MIF. In case of double transfectants, Western blots 
using the anti-MIF antibody detect a 22 kDa slower-migrating biotin.MIF (Figure 10, upper 
panel, lane 2, arrow) and 12 kDa endogenous MIF (Figure 10, upper panel, lane 2, and star) in 
cell extracts. For single transfectants, only the endogenous MIF was detected (Figure 10, lane 
3). Next, the successful biotinylation of MIF was confirmed by biotin detection in cell lysates. 
An increased signal was only detectable in double transfectants (Figure 10, lower panel, lane 
2, arrow). No biotinylation was detected in the single transfectant (Figure 10, lower panel, 
lane 3). These data demonstrate the efficient biotinylation of MIF by BirA in NIH 3T3 cells.  
 
 
 
Figure 10: Efficiency of biotinylation of MIF and single-step purification.  
Cytoplasmic extracts from NIH 3T3 cells expressing biotin.MIF and biotin ligase birA (lanes 
2, 4 and 6) or birA only (lanes 3, 5 and 7) were incubated with streptavidin agarose beads. 
Supernatants (unbound, lanes 6 and 7), bound proteins (lanes 4 and 5) and input lysate (lanes 
2 and 3) were subjected to 18% SDS-PAGE followed by Western blotting (WB) for MIF 
(upper blot) and biotin (lower blot). Endogenous and recombinant MIF (rMIF) are indicated 
by asterisk and biotin.MIF is marked by arrows.  
 
Following the confirmation of the successfull in vivo biotin tagging, biotin.MIF 
together with its associated binding proteins were purified from cell extracts by affinity 
chromatography using streptavidin coated beads. The optimum binding ratio of total protein 
extracts to streptavidin beads was determined using different amounts of protein extracts and 
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different incubation times (data not shown). The complete protein extracts (Figure 10, lane 2 
and 3), bound material (Figure 10, lane 4 and 5) and unbound supernatants (Figure 10, lane 6 
and 7) were analyzed by Western blotting. As shown in figure 10 (lower panel) a number of 
endogenously biotinylated proteins bound to streptavidin-HRP were also visible. Taken 
together, these results indicate that biotin.MIF is efficiently recovered from cell extracts by 
single-step affinity purification. 
5.1.2. Purification and visualization of MIF associated proteins 
 
After single step purification by direct binding to streptavidin beads, biotin.MIF was 
almost completely recovered from extracts as hardly any biotin.MIF could be detected in 
supernatants. The efficiency of affinity purification was further confirmed by Coomassie blue 
stained gel of the cell extracts binding to streptavidin beads (Figure 11). Biotin.MIF was only 
detected in the double transfectants. The presence of biotin.MIF was confirmed by excising 
the respective band from the gel. The staining pattern of the lane with the co-purified proteins 
together with biotin.MIF (Figure 11, lane 3) was significantly different to that observed with 
the background binding (lane 4) indicating enrichment of MIF interacting partners copurified 
with biotin.MIF. The entire lane from double and single transfectant was excised and divided 
into corresponding gel pieces subsequently analyzed by mass spectrometry.  
 
 
 
Figure 11: Coomassie blue stained gel of purified biotin.MIF and its interacting 
partners.Proteins from biotin.MIF and birA (lane 3) and birA only (lane 4) expressing cells 
bound to streptavidin beads. M = molecular weight marker (lane 1), rMIF (lane 2). 
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After mass spectrometry analysis, proteins identified in both transfectants (Figure 11, 
lane 3 and lane 4) were compared to each other. Because biotin.MIF and co-purified proteins 
(lane 3) may compete for binding with the endogenously expressed biotinylated proteins 
observed in lane 4, the proteins in single transfectant (Figure 11, lane 4) were further 
excluded. The proteins identified from 1D-SDS-PAGE, their identities, corresponding NCBI 
accession numbers and matched peptide fragments are listed in Table III. Identified proteins 
included the well known MIF binding partners peroxiredoxin–1 and RPS 19 (unpublished 
data). 
 As it is possible that addition of the peptide tag or biotinylation may affect the 
properties of the tagged MIF, it was tested whether biotin.MIF could still undergo protein–
protein interactions with established MIF partners such as Jab1/CSN5, peroxiredoxin-1. After 
pull-down of biotin.MIF Jab1/CSN5, peroxiredoxin-1 (Prx-1) and RP S19 was found to be 
retrieved from cell extracts expressing biotin.MIF (Figure 12, lane 3), but not from extracts 
expressing BirA only (Figure 12, lane 4). 
 
Figure 12: Single step biotin pull-down of MIF together with known interacting 
proteins. Cell extracts expressing biotinylated MIF and birA (lanes 1 and 3) and birA only 
(lanes 2 and 4) were incubated with streptavidin beads. Input (lanes 1 and 2) and bound 
proteins (lanes 3 and 4) were resolved on a 15% SDS gel and analyzed by immunoblotting 
using antibodies for Jab1/CSN5, peroxiredoxin-1 (Prx-1) and RPS 19 (upper panels) and 
biotin (lower panel).  
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5.1.3. TEV-digest on beads and 1D-SDS-PAGE 
 The specific TEV protease cleavage site present on the biotinylation tag (see figure 9) 
was used to cleave and elute the tagged protein complex from the streptavidin beads. Beads 
carrying protein complexes obtained from double and single transfected cells were washed 
and incubated with the TEV protease. In order to increase protein concentrations, TEV eluates 
from 3 experiments were combined and proteins subsequently precipitated with acetone. 
Proteins were separated by 1D-SDS-PAGE and stained with Coomassie blue (Figure 13). 
 
Figure 13: Coomassie blue stained gel of cytoplasmic extracts obtained after binding to 
streptavidin beads with subsequent elution of bound proteins by cleavage with TEV.  
Lane 1: molecular weight marker, lane 2: rMIF, lane 3: eluted proteins from cells expressing 
biotin.MIF and BirA, lane 4: eluted proteins from cells expressing BirA only.  
5.1.4. 2D-SDS-PAGE analysis of protein complexes obtained after TEV protease reaction 
 In order to obtain a better separation and resolution of purified proteins, TEV eluates 
from both double and single transfectants were applied to 2D-SDS-PAGE and stained with 
Silver staining (Figure 14). Proteins spots occurring only in double transfected cells were 
exzised from silver stained gels and subjected to in-gel trypsin digestion followed by 
MALDI-MS analysis. Proteins identified by peptide mass fingerprinting analysis are listed in 
table IV. A total of 30 gel spots were subjected to analysis. Amongst them 4 gene products 
were also found in 1D-SDS gel analysis of the single-step affinity purification (Figure 11 and 
table III).  
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Figure 14: 2D-SDS-PAGE of proteins eluted after TEV protease treatment. 
Protein spots from cells expressing biotinylated MIF and BirA (upper panel) were compared 
with spots from cells expressing BirA only (lower panel). Proteins that were found only in 
cells expressing biotinylated MIF and BirA were exzised from the gel, digested with trypsin, 
and identified by MALDI-MS and peptide mass fingerprinting analysis. The numbers in the 
upper panel refer to the list of identified proteins in table IV. 
5.1.5. Co-immunoprecipitation of MIF interacting proteins from NIH 3T3 cells 
 
 To verify the in vivo biotin tagging approach, the results obtained by MALDI-TOF 
were reproved with an independent method, i.e. co-immunoprecipitation (co-IP). 
Peroxiredoxin-1, Fetuin, Pgk-1, RPS 19 and VCP were co-precipitated with MIF (Figure 
15A). Extracts from mouse NIH 3T3 fibroblast cells were subjected to co-IP with a polyclonal 
rabbit anti-rat MIF antibody or with a rabbit control preimmune serum which were previously 
immobilized on protein G-Sepharose beads. The immune complexes were probed for 
Peroxiredoxin-1, VCP, Fetuin, RPS 19, Jab1/CSN5 and Pgk-1, stripped and reprobed for MIF 
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by Western blot analysis. As shown in Figure 15A, anti-MIF antibody efficiently precipitated 
MIF together with Peroxiredoxin-1, VCP, Fetuin, Pgk-1 and RPS 19 from NIH 3T3 cell 
lysates. Additionally, mouse and bovine Fetuin were precipitated with MIF (Figure 15B). 
Importantly, reverse co-IP with anti-RPS 19 antibody followed by anti-MIF Western blot 
analysis confirmed the interaction (Figure 15C). To further solidify the interaction between 
endogenous MIF and RPS 19 cell lysates were subjected to immunoprecipition with anti-
mouse RPS 19 antibody and mouse Ig control antibody. Immunoprecipitates were analyzed 
by Western blotting using anti-MIF antibody. 
 
Figure 15: Interaction between endogenous MIF and its binding partners in NIH 3T3 
cells. (A) Cell lysates were subjected to immunoprecipitation (IP) with either a rabbit anti-
MIF antiserum (lane 2) or rabbit pre-immunserum (lane 3). Co-immunoprecipitated proteins 
were analyzed by Western blotting as indicated. (B) Mouse and bovine serum were assessed 
with anti-MIF (lane 2) and control (lane 3) IP. Immunoprecipitated proteins were detected 
with anti-fetuin antibody. (C) Interaction between MIF and RPS 19 was further confirmed by 
reciprocal IP with a monoclonal RP S19 antibody (right panel, lane 2) and isotype control 
antibody (right panel lane 3). The amount of input is 5% of cell lysate (lane 1). 
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5.1.6. Co-localization of MIF and its interacting partners 
 
The interaction between MIF and its associated proteins was further confirmed by 
revealing a cytoplasmic co-localization of proteins with confocal microscopy (Figure 16).  
 
 
Figure 16: Co-localization of MIF and its interacting proteins in NIH 3T3 cells. 
Cells were double immunostained using antibodies raised against MIF and VCP, RPS 19 or 
Pgk-1, respectively, followed by decoration with fluorescently labeled secondary antibodies. 
MIF is shown in red (A), interacting proteins in green (B) Regions with co-localized proteins 
appear orange in the overlay (C). 
 
1D- and 2D-SDS-PAGE results indicate that the screening approach used in this study 
permits the identification of novel MIF interaction partners. A recent study has shown that 
MIF regulates the activity of SCF ubiquitin ligases, which are known to play a pivotal role in 
UPS (ubiquitin proteasome system) (Nemajerova et al., 2007a). Of note, VCP an important 
component of the UPS, was identified as a new MIF-binding partner in the 2D-SDS-PAGE 
analysis in this study with the highest peptide score. This prompted us to investigate the 
association of MIF and VCP further. 
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5.1.7. Characterization of protein domains involved in interaction between MIF and VCP 
 
To investigate the binding domains involved in the interaction between MIF and VCP, 
the N-terminal domain (residues 1–202), D1 domain (residues 203–450), D2 domain 
(residues 451–807) and ND1 domain (residues 1–450) of VCP were co-expressed with MIF 
in NIH 3T3 cells, respectively. Cell lysates from transfected cells were subjected to MIF-IP 
and precipitated proteins were detected with an anti-FLAG antibody. However, none of the 
domains of VCP were precipitated together with MIF (Figure 17B).  
Additionally, surface plasmon resonance analysis performed on a Biacore system with 
the purified recombinant proteins was applied to examine if the interaction between MIF and 
VCP is direct. However, the dissociation constant of formation of the MIF-VCP complex was 
not in the range that are commonly observed for protein-protein interactions (cooperation with 
Carlsson-Skwirut, C, Karolinska Institute, Sweden).  
Furthermore, FRET (Fluorescence resonance energy transfer) was used to explore if 
the molecular proximity between MIF and VCP is closer than 10nm. Although both VCP and 
MIF were found in the cytoplasm, no significant FRET signal was detected. These results lead 
to the hypothesis that the interaction between MIF and VCP could be indirectly mediated by a 
linking cofactor. Amongst known MIF interacting proteins, a potential candidate is 
Jab1/CSN5. This factor is also involved in the UPS like VCP. To verify if Jab1/CSN5 may 
serve as a cofactor of VCP, full lenght VCP and its mutants carrying a FLAG tag (Figure 
17A) were coexpressed together with wt-Jab1/CSN5 in NIH 3T3 cells. After Jab1/CSN5 
pulldown (Figure 17C) only the ND1 domain (lane 11) and full lenght VCP (lane 12), but not 
the N-terminal domain, the D1 domain or the D2 domain were pulled down together with 
Jab1/CSN5.  
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Figure 17: Interaction domains of VCP with MIF and Jab1/CSN5. 
(A) Diagram displaying VCP and deletion constructs carrying N-terminal FLAG (FL) tag 
(B+C) Full length VCP or the N-terminal domain (residues 1–202), D1 domain (residues 
203–450), D2 domain (residues 451–807) or ND1 domain (residues 1–450) of VCP were 
ectopically expressed as FLAG-tagged fusion proteins in NIH 3T3 cells. As a control, cells 
were transfected with the VCP expression vector (V). Simultaneously, MIF (B) and 
Jab1/CSN5 (C) were co-expressed ectopically. MIF and Jab1/CSN5 were pulled-down from 
supernatants of lysed cells using an anti-MIF and anti-Jab1/CSN5 antibodies (lane 7-12). 
Precipitated proteins were detected by IB with an anti-FLAG antibody (IP: MIF and IP: 
Jab1/CSN5; lane 7–12). Expression of FLAG, MIF and Jab1/CSN5 constructs in cell lysates 
was detected by immunoblotting (IB) (input; lanes 1–6). 
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5.2. MIF interacts with VCP via Jab1/CSN5 
5.2.1. Jab1/CSN5 interacts with VCP in vivo and in vitro 
 
The verification of specific and direct interaction between VCP and Jab1/CSN5 was 
determined by performing co-IP and in vitro pull-down experiments. Initially, the interaction 
of the endogenous partners with normal expression levels was investigated in vivo. 
Endogenous Jab1/CSN5–VCP complexes were precipitated from NIH 3T3 and HEK293T 
cells by using anti-Jab1/CSN5 (Figure18A, lane 2) and anti-VCP (Figure 18B, lane 2) 
antibodies. The cell lysates used for IP was analyzed for VCP and Jab1/CSN5 expression 
(Figure 18A and B, lane1). Using isotype control antibodies (Figure 18 A+B, lane 3) no co-
precipitation was visible.  
 Furthermore, in order to confirm the interaction between VCP and Jab1/CSN5 
ectopically, FLAG-VCP was expressed in NIH 3T3 cells (Figure 18C, lane 2). Cell lysates 
were prepared and incubated with monoclonal anti-FLAG M2 agarose gel. Precipitated 
proteins were analysed by Western blotting. As shown in Figure 18C, endogenous Jab1/CSN5 
was pulled-down with FLAG-VCP (lane 4), whereas no precipitation of Jab1/CSN5 was 
observed when cells were transfected with VCP expression vector only (lane 3).  
Moreover, in vitro pull-down assays were performed to examine a potential direct 
interaction between Jab1/CSN5 and VCP. For this purpose, increasing concentrations of His-
VCP (Figure 18D, lane 1: 0.25 µg, lane 2: 0.50 µg, lane 3: 1 µg, lane 4: 2 µg) were incubated 
with 1µg of recombinant GST-Jab1/CSN5 immobilized on glutathion agarose beads. As a 
control, glutathion agarose was incubated with 2 µg of His-VCP (lane 5). After washing the 
beads, GST-Jab1/CSN5 bound proteins were detected by immunoblotting (Figure 18D). In 
this experiment, increasing amounts of His-VCP were copurified together with GST-
Jab1/CSN5. However, His-VCP did not show unspecific affinity to glutathion. Taken together 
this suggests a direct interaction of both proteins in vitro. 
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Figure 18: Interaction between Jab1/CSN5 and VCP in vivo and in vitro. 
 (A) Lysates from NIH 3T3 and HEK293T cells were analyzed for VCP and Jab1/CSN5 
expression by immunoblotting (IB) (input, lane 1). Respective cell lysates were used for 
immunoprecipitation (IP) with anti-Jab1/CSN5 antibody (lane 2) and isotype control antibody 
(control, lane 3) (B) Reciprocal IP was performed using anti-VCP antibody (lane 2) and 
isotype control IgG (lane 3). Immunoprecipitates were analyzed with anti-VCP and anti-
Jab1/CSN5 antibodies by immunoblotting. (C) Jab1/CSN5 expression was analyzed in NIH 
3T3 cells transfected with empty VCP expression vector (lane 1) or FLAG-VCP (lane 2). In 
the supernatant of lysed cells, FLAG-VCP (lane 4) was pulled-down using anti-FLAG 
antibody. Co-precipitated Jab1/CSN5 was detected by immunoblotting using specific 
antibody (lane 4). Transfection of empty VCP expression vector served as control for 
specificity of IP (lane 3). (D) His-VCP interacts with purified GST-Jab1/CSN5. Immobilized 
GST-Jab1/CSN5 was incubated with increasing amounts of purified His-VCP (lane 1-4). 
Binding of His-VCP to GST-Jab1/CSN5 was detected using anti-VCP antibody (lane 1-4, 
top). Equal amounts of GST-Jab1/CSN5 (1 µg) were used in the experiments (lane 1-4, 
bottom). As control, beads without bound GST-Jab1/CSN5 were incubated with 2 µg of His-
VCP (lane 5). Input of His-VCP: 0.25 µg (lane 1); 0.5 µg (lane 2); 1 µg (lane 3); 2 µg (lane 4 
and 5). 
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5.2.2. Domains involved in interaction between Jab1/CSN5 and VCP 
 
 Previous results in this study showed that Jab1/CSN5 binds to the ND1 domain of 
VCP (see 5.1.7, figure 17B). To further investigate the domains of Jab1/CSN5 essential for 
the interaction with VCP, FLAG-VCP, Myc-Jab1/CSN5 and Myc-Jab1/CSN5 deletion 
mutants (1–191, 1–110, 110–191) were coexpressed in HEK293T cells. A schematic 
illustration of Jab1/CSN5 and its deletion mutants is described in Figure 19A. Lysates of 
these transfected cells were prepared and further applied to FLAG-IP (Figure 19B). FLAG-
VCP was pulled-down using an anti-FLAG antibody and co-precipitated Myc-Jab1/CSN5 and 
its deletion mutants were detected by immunoblotting using an anti-Myc antibody. 
Transfection of Myc-Jab1/CSN5 expression vector served as control for specificity of IP. 
Immunoprecipitation data indicated that wt-Jab1/CSN5 and its deletion mutants 1–110 and 1–
191 bind to FLAG-VCP (Figure 19B, lanes 7, 8, 9), whereas the 110–191 deletion mutant is 
ineffective (Figure 19B, lane 10). This showed that full lenght Jab1/CSN5 and its 1–191 
deletion mutant which harbors an intact Jab1/MPN/Mov34 metalloenzyme motif (MPN) 
interacts with VCP.  
The JAMM motif of the MPN domain is required for the degradation of ubiquitin-
proteasome substrates. A mutation of histidines to alanine in the predicted active site 
stabilized substrates of the ubiquitin pathway (Verma et al., 2002). Since the 110-191 domain 
of Jab1/CSN5 did not show any interaction, further studies were attempted to investigate 
whether VCP-Jab1/CSN5 interaction depends on the JAMM motif of Jab1/CSN5. For this 
purpose, a Myc tagged-JAMM mutant of Jab1/CSN5, in which a histidine residue is changed 
to alanine, was co-expressed with FLAG-VCP in HEK293T cells. Lysates of transfected cells 
were applied to Myc and FLAG-IP, respectively. As shown in Figure 19C, the Myc-JAMM 
mutant Jab1/CSN5 was pulled-down together with FLAG-VCP (Figure 19C, lane 4) and 
reciprocally, FLAG-VCP was pulled-down together with Myc-Jab1/CSN5 (Figure 19C, lane 
8). Cell lysates used for IP experiments are shown in lane 1, 2 and 5, 6. Both FLAG and Myc 
pull-down assays showed that Jab1/CSN5–VCP interaction is independent of the JAMM 
motif (Figure 19C).  
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Figure 19: Domains of Jab1/CSN5 involved in interaction with VCP 
(A) Schematic illustration of Jab1/CSN5 and its deletion mutants. (B) Interaction of FLAG-
VCP with the N-terminal domain of Jab1/CSN5. The plasmids expressing FLAG-VCP and 
Myc-Jab1 (WT, 1-334), the deletion mutants Myc–1–110, Myc–1–191 or Myc–110–191 were 
co-transfected into HEK293T cells. Respective expression (input, lane 1–5) and FLAG-IP 
(lanes 6–10) were detected using anti-FLAG or anti-Myc antibodies. The asterix indicates 
presence of the heavy chain of IgG. (C) Interaction of JAMM mutant-Jab1/CSN5 with VCP. 
Plasmids expressing FLAG-VCP and Myc-Jab1/CSN5 mutant were co-transfected in HEK 
293T cells. Inputs (lane 1, 2, 5 and 6) and IP (lane 3, 4, 7 and 8) were detected by 
immunoblotting using anti-Myc and anti-FLAG antibodies. 
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5.2.3. FRET-CLSM analysis of Jab1/CSN5-VCP association  
 
To investigate whether VCP and Jab1/CSN5 proteins are localized in such proximity 
in cells that protein-protein interaction is likely, FRET combined with CLSM was applied 
(Truong and Ikura, 2001; Konig et al., 2006). Proteins were co-expressed in NIH 3T3 cells 
and detected by indirect double-immunofluorescence. Overexpressed VCP and Jab1/CSN5 
were detected primarily in the cytoplasm. In acceptor bleaching experiments, the fluorescence 
of the donor (VCP, Cy3 labeled) and of the acceptor (Jab1/CSN5, Cy5 labeled) were 
determined and their intensities were measured before and after the Cy5 fluorophore 
bleaching in a defined region of interest (ROI). Photobleaching of the acceptor (Jab1/CSN5) 
fluorophore (Cy5) led to an almost complete removal of the pseudocolored fluorescence 
intensity (Figure 20D). In donors of the Cy3 (donor) channel, an concominant increase was 
detected in the same ROI (Figure 20B). A total of eighteen to twenty cells in each experiment 
( n=76 for the experimental group and n=85 for the control group obtained from 4 different 
experiments) were analysed. Positive FRET signal was robustly detected in every experiment. 
A distinct increase of fluorescence (ΔIF) was observed in the bleached area with a median 
value of 7.87 ( Figure 20E). A false-positive FRET signal that can potentially be caused by 
unspesific cross-reactivity of the secondary antibodies was excluded by performing control 
experiments. Here, both secondary antibodies were applied in an incubation with anti-
Jab1/CSN5 antibody (acceptor) only (median ΔIF = 2.75) (Figure 20E).  
 
 
Figure 20: Close proximity of VCP and Jab1/CSN5 proteins in NIH 3T3 cells shown by 
double-labeling indirect immunofluorescence (IF) combined with FRET analysis. 
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Immunofluorescence detection of VCP (donor labeled with Cy3-conjugated secondary 
antibody; A and B) and Jab1/CSN5 (acceptor labeled with Cy5-conjugated secondary 
antibody; C+D). Cy5 was bleached in region of interest (ROI) 1 (compare ROI 1 in C and D). 
ROI 2-5: control areas outside the bleached area. (E) Changes in ΔIF in experimental 
compared to control group. ***=p ≤ 0.001, Mann-Whitney test; n = number of measurements 
(4 experiments). Boxplots: percentiles 0, 25, median, 75, 100. O: extreme values of data set. 
Bar: 20µm 
 
5.2.4. Interactions between VCP and COP9 signalosome (CSN) subunits 
 
 The CSN complex, also known as the Jab1/CSN5-containing signalosome, consists of 
eight subunits termed CSN1-CSN8 (Deng et al., 2000). The interaction of Jab1/CSN5 with 
VCP found in this study prompted us to investigate whether the other subunits of the CSN 
complex also interact with VCP. To verify this hypothesis CSN1 pull-down experiments were 
performed. CSN1-based pull-downs have been shown previously to efficiently precipitate the 
entire CSN complex (Tsuge et al., 2001).Pull-down of the CSN complex by an anti-CSN1 
antibody revealed that the CSN complex indeed interacts with VCP (Figure 21A). Pull-down 
specificity was confirmed by immunoblotting with a Jab1/CSN5 antibody (Figure 21A). 
 
 
Figure 21: Interaction of VCP with the entire CSN complex and the proteasome lid 
 (A) Cell lysates from HEK293T cells were analyzed for expression of VCP, Jab1/CSN5 and 
CSN1 by immunoblot analysis (IB, lane 1). Subsequently, lysates were subjected to co-IP 
using anti-CSN1 antibody (lane 2) and isotype control antibody (lane 3). Using immunoblot 
analysis, separated proteins were probed with anti-VCP antibody and anti-Jab1/CSN5 
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antibody, followed by stripping and reprobed with anti-CSN1 antibody to confirm pull-down 
of the whole CSN complex (B) Copurification of VCP and Jab1/CSN5 with the proteasome 
subunit RPN 11 in a Sephacryl S-200 column. HEK293T cell lysates were separated using gel 
filtration. Fractionated proteins were resolved in a 12.5% SDS-PAGE and immunoblot 
analysis was performed using the antibodies indicated on the left. Fraction numbers are 
provided at the bottom of the picture (C) RPN-11 immunoprecipitation (IP) was performed 
using fractions 5 and 6 and the presence of CSN1, VCP, Jab1/CSN5 and PRN11 were verified 
in precipitates using specific antibodies (lane 2). Isotype control antibody was applied as 
control (lane 3). Lane 1: 2% of input.  
 
5.2.5. Interaction of VCP with Jab1/CSN5 in the proteasome lid complex (RPN 11/S13)  
 
VCP has been shown to copurify and coimmunoprecipitate with the 26S proteasome, 
to have ATPase activity, and to be a multiubiquitin chain-targeting factor required for 
degradation by the ubiquitin-proteasome pathway (Dai and Li, 2001). However, it has not 
been shown which subunit of the proteasome interacts directly with VCP. Since Jab1/CSN5 
and the proteasome lid complex subunit (RPN 11) share the same domain (MPN+ or JAMM), 
it is possible that VCP could also interact with the lid complex of the proteasome. To study 
this hypothesis, total protein extracts from HEK293T cells were prepared and resolved by gel 
filtration chromatography using a Sephacryl S-200 column. Fractions were analyzed by 
immunoblotting to identify if RPN 11 containining fractions also show VCP and Jab1/CSN5. 
RPN11 was found in fractions 5-7 (Figure 21B). VCP and Jab1/CSN5 were observed in 
fractions 5 and 6 suggesting an association with the proteasome. To confirm the hypothesis 
that Jab1/CSN5 and VCP interact with RPN 11, cell lysates of fractions 5 and 6 were used for 
immunoprecipitation of RPN 11. Precipitated proteins were analyzed by immunoblotting for 
using antibodies directed aginst VCP and CSN subunits. Interestingly, RPN 11 appears to 
interact stronger with CSN than VCP (Figure 21C). 
 
5.2.6. Jab1/CSN5-polyubiquitin interaction in vivo and in vitro 
 
 The Jab1/CSN5-VCP interaction found in this study raised the question whether 
Jab1/CSN5 could interact with ubiquitin chains via the MPN domain, a known ubiquitin 
binding domain. Binding of gold labelled polyubiquitin chains (Ub4) to the CSN was 
demonstrated by electron microscopical study (Hetfeld et al., 2005). It remained, however, 
unanswered to which subunit of CSN binds to polyubiquitin chains. For this reason, 
Jab1/CSN5-ubiquitin binding was examined in vitro and in vivo. To examine the Jab1/CSN5-
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ubiquitin association in vitro, purified GST-Jab1/CSN5 was immobilized an Glutathion 
Sepharose beads and incubated with Lys48-linked polyubiquitin chains (Ub2–7). In vitro 
binding was detected by immunoblotting using anti-ubiquitin antibodies (Figure 22a, lane 3 
and 4). 
 Since the MPN domain of proteins is known to interact with ubiquitin chains 
(McCullough et al., 2004; Bellare et al., 2006; Hurley et al., 2006), it was aimed to define 
whether Jab1/CSN5 interacts with these ubiquitin chains directly via its MPN domain in vivo. 
Therefore, Myc-Jab1/CSN5 and its deletion mutants (1–191, 1–110, 110–191) were 
overexpressed in HEK293T cells. Lysates were immunoprecipitated using an anti-Myc 
antibody and immunoblot analysis was performed with anti-ubiquitin antibodies (Figure 22b). 
As shown in figure 22b, Jab1/CSN5 binds to ubiquitinylated proteins via the N-terminal 
region harboring the MPN domain (1-191). The 110–191 domain also binds to ubiquitinylated 
proteins, but in a weaker fashion than the wild type. These results demostrate that Jab1/CSN5 
indeed binds to ubiquitinylated proteins via its MPN domain. 
VCP is also known to interact with polyubiquitinylated proteins by either binding to 
them directly with its N-domain or indirectly mediated by cofactors (Dai and Li, 2001). In 
this study, VCP-polyubiquitin association was used as a positive control. In order to define 
VCP-polyubiquitin association in vitro, purified His-VCP was immobilized on Ni-NTA 
agarose beads and incubated with Ub(2-7). Binding was detected using immunoblotting 
(Figure 22A, lane 6). However, no differences between VCP-polyubiquitin and Jab1/CSN5-
polyubiquitin association were detected, suggesting that Jab1/CSN5 binds to ubiquitinylated 
proteins (lane 3 and 4) with the same affinity as shown in association with VCP-polyubiquitin 
(lane 6). 
After proving that both VCP and Jab1/CSN5 bind to ubiquitin chains, the possibility 
that Jab1/CSN5 and VCP may compete for binding to polyubiquitin chains (Ub2-7) was 
examined. For that, immobilized His-VCP was loaded with polyubiquitin chains and 
increasing amounts of GST- Jab1/CSN5 (lane 8: 0.50 µg and lane 9: 1 µg) were passed over 
the washed column. GST- Jab1/CSN5 was able to compete with His-VCP for polyubiquitins 
and thus partially removed polyubiquitin chains from the column. These results showed that 
GST-Jab1/CSN5 interacts with both His-VCP and ubiquitin chains. Additionally, GST-
Jab1/CSN5 competes with VCP for binding to ubiquitin chains.  
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Figure 22: Jab1/CSN5 –polyubiquitin association in vitro and in vivo.  
(A) Binding of Jab1/CSN5 to polyubiquitinated proteins in vitro. Polyubiquitin chains (Ub2–
7) were incubated both with GST-Jab1/CSN5 immobilized on glutathione-Sepharose 4B and 
His-VCP immobilized on Ni-NTA agarose in vitro. Bound proteins were resolved using SDS-
PAGE and polyubiquitin chains associated with GST-Jab1/CSN5 (lane 3 and 4) and His-VCP 
(lane 6) were detected by immunoblotting using anti-ubiquitin antibodies. Lane 1: 100 ng Ub 
(2-7), lane 2: GST, lane 5: 200 ng GST-Jab1/CSN5, lane 7: 200 ng His-VCP, lane 10: Ni-NTA 
agarose. GST-Jab1/CSN5 (lane 8: 0. 5 µg and lane 9: 1 µg) was added to immobilize His-
VCP-polyubiquitin. Bound proteins were resolved by SDS-PAGE and polyubiquitin chains 
were detected by immunoblotting using anti-ubiquitin antibodies (B) Binding of Jab1/CSN5 
to polyubiquitinated proteins in vivo. HEK293T cells transfected with Myc-Jab1/CSN5 
expression vector, wt-Myc-Jab1/CSN5 and the deletion mutants of Myc-Jab1/CSN5. Cells 
were lysed and immunoprecipitated with a monoclonal anti-Myc antibody. Precipitates were 
analyzed by immunoblotting using anti-Myc and anti-ubiquitin antibodies. (C) Jab1/CSN5 
effect on VCP-polyubiquitin protein binding. HEK293T cells were transfected with HA-
ubiquitin, FLAG-VCP and either Myc-Jab1/CSN5 expression vector or wt-Jab1/CSN5 as well 
as mutants of Jab1/CSN5. FLAG-VCP was precipitated and the associated ubiquitin proteins 
were determined by immunoblotting using an anti-ubiquitin antibody.  
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5.3. Jab1/CSN5 regulates VCP-polyubiquitin association 
 
 The main function of VCP is to escort ubiquitinylated proteins to the proteasome and 
segregate these ubiquitinylated proteins from their binding partners. After extraction of 
ubiquitinylated substrates from their partners with the aid of a number of substrate-recruiting 
cofactors, the segregated proteins can either be polyubiquitinylated or deubiquitinylated by a 
number of substrate-processing cofactors (Jentsch and Rumpf, 2007). Because Jab1/CSN5 in 
association with the CSN complex is known to possess deubiquitinylase activity (Hetfeld et 
al., 2005), it is suggested that Jab1/CSN5 may regulate the ubiquitinylation status of proteins 
bound to VCP. To find out whether the Jab1/CSN5-VCP interaction affects the VCP-
polyubiquitin association, HEK293T cells were transfected with FLAG-VCP, HA-ubiquitin 
and either Myc-Jab1/CSN5 or its deletion mutants. Cell lysates were used for 
immunoprecipitation of FLAG-VCP in vivo. Immunoprecipitated proteins were blotted and 
probed with an anti-ubiquitin antibody. The number of the ubiquitinylated proteins 
precipitated together with VCP was decreased in Jab1/CSN5 transfected cells compared to 
cells transfected with Jab1/CSN5 expression vector and the JAMM mutant of Jab1/CSN5 
(Figure 22C). In addition, the proteasome inhibitor MG132 was used to block VCP-mediated 
degradation of ubiquitinylated substrates in the experimental setup (Figure 23A). A clear 
difference between Jab1/CSN5 transfected cells and its mutants was observed by means of 
VCP-polyubiquitin association. Polyubiquitin conjugated proteins bound to VCP were found 
to accumulate in the JAMM mutant of Jab1/CSN5 transfected cells, whereas no significant 
change was observed in wild type Jab1/CSN5 transfected cells (Figure 23A).  
These results showed that Jab1/CSN5 reduces VCP-polyubiquitin association, 
suggesting that Jab1/CSN5 could be a new key substrate-processing cofactor that 
deubiquitinylates the substrates bound to VCP. 
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Figure 23: Functional CSN complex with associated USP15 deubiquitinase regulates 
deubiquitinylation of polyubiquitinated substrates bound to VCP  
(A) HEK 293T cells were transfected with empty vector, Jab1/CSN5 (wtCSN5) or the JAMM 
mutant of CSN5 (mCSN5) and treated with the proteasome inhibitor MG132. VCP was 
immunoprecipitated (IP) from transfected cell lysates, and precipitates were analyzed by 
immunoblotting (IB) for ubiquitin, VCP and CSN5. β-actin was used as loading control. (B) 
Cells were transiently transfected with control, CSN1, CSN5 and USP15 siRNAs. After 
treatment with the proteasome inhibitor MG132 for 1 h cell lysates were analyzed by IB using 
specific antibodies as indicated on the left. After immunoprecipitation of VCP, ubiquitin was 
detected in precipitates by IB. Asterisks denote IgG heavy chains, # indicates Myc-tagged 
CSN5 JAMM mutant. (C) Functional controls: lysates of CSN5-knockdown cells were 
analysed by IB for the presence of CSN5, cullin1, IκBα, CSN1 and ß-actin (upper panel). 
Lysates of mCSN5-transfected cells were analysed by IB for the presence of CSN5, cullin 1 
and ß-actin (lower panel).  
 
 
 Since Jab1/CSN5 exerts its activities within the CSN complex, the functional effect of 
CSN on the VCP-polyubiquitin association was examined by RNA interference (Figure 23B). 
Jab1/CSN5 and CSN1 were efficiently knocked down in HEK 293T, which leads to 
destabilisation of the CSN complex and polyubiquitinylated proteins bound to VCP were 
detected with an anti-ubiquitin antibody. The amount of ubiquitinylated proteins associated 
with VCP is increased in Jab1/CSN5 and CSN1 knockdown cells compared to control cells 
(Figure 23B, lane 6, 7). This confirmed preview results (Figure 22C and 23A) and suggested 
that the JAMM motif of Jab1/CSN5 (mCSN5) and the CSN complex are required for the 
deubiquitinylation of ubiquitinylated substrates bound to VCP. Because the CSN is associated 
with the deubiquitinase USP15 (Hetfeld et al., 2005), USP15 was also knocked down. Like in 
CSN1 and Jab1/CSN5 knock down experiments polyubiquitinylated proteins bound to VCP 
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were found to accumulate in USP15 knockdown cells (Figure 23B, lane 8). Therefore, this 
finding proposes that the activity of USP15 is involved in determining the fate of substrates 
bound to VCP. The functionality of the knockdown was examined for Jab1/CSN5 (Figure 
23C upper panel). Knockdown of Jab1/CSN5 significantly increased the fraction of 
neddylated cullin 1 as the CSN function is impaired due to inapproriate synthesis of CSN1 or 
5, which results in loss of deneddylation. The same effect was observed when the JAMM 
mutant of Jab1/CSN5 (mCSN5) was overexpressed (Fig. 23C lower panel) demonstrating that 
the mutant protein is indeed compromising CSN deneddylase activity. Moreover, IκBα 
accumulated in the Jab1/CSN5 knockdown (Fig. 23C upper panel) due to deregulated 
deubiquitination by USP15. 
5.4. Knockdown of Jab1/CSN5 delays the degradation of ubiquitinylated proteins  
 
It was shown that VCP-Jab1/CSN5 association regulates the fate of the ubiquitinylated 
proteins in this study (see 5.3). This raised the question if the association could also affect the 
TNFα inducuded degradation of IκBα, an important and well established substrate for the 
UPS. Therefore, HEK293T cells were transfected either with Jab1/CSN5siRNA or controlsiRNA 
and subsequently stimulated with TNFα (10 ng/ml) for 0-45 min. Lysates were separated 
using SDS-PAGE and probed with antibodies directed against IκBα, Jab1/CSN5 and β–actin. 
In cells transfected with controlsiRNA IκBα was degraded within 5 min after TNFα induction 
(Figure 17). However, in HEK293T cells transfected with Jab1/CSN5siRNA, TNFα-induced 
IκBα degradation was delayed. The efficiency of the Jab1/CSN5 knockdown was confirmed 
by immunoblotting. 
 
 
Figure 24: TNFα induced degradation of IκBα is delayed by Jab1/CSN5siRNA  
HEK293T cells were transfected with either Jab1/CSN5siRNA or controlsiRNA for 72 h and 
subsequently stimulated with TNFα (10 ng/ml) for the indicated periods of time. Lysates were 
probed using immunoblotting (IB) with antibodies directed against IκBα, Jab1/CSN5 and β–
actin (loading control). 
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 Taken together, the results of the knockdown experiments support the hypothesis that 
Jab1/CSN5 is a key substrate processing factor that deubiquitinylates VCP bound substrates 
such as IκBα (Figure 23, 24). 
5.5. Knockdown of MIF, VCP and Jab1/CSN5 with different RNAi strategies 
 
RNA interference (RNAi) is a novel gene regulatory mechanism by which double-
stranded RNA (dsRNA) induces gene silencing by targeting complementary mRNA for 
degradation. It reduces the expression of a particular gene in nearly all metazoan systems, 
often by 70-90% or greater and effects the cellular function of the respective gene. The 
mechanism of RNA interference (RNAi) is summarized in Figure 25.  
 
 
Figure 25: Three Ways to Trigger the RNAi Pathway.  
In mammalian systems, RNAi can be triggered by synthetic short interfering RNA (siRNA) 
molecules (pathway 2) or by DNA based expression vectors designed to express short hairpin 
RNA (shRNA) molecules (pathway 1). In non-mammalian systems, the RNAi pathway 
commences when double-stranded RNA (dsRNA; usually longer than 30 bp) is introduced 
into cells (pathway 3). In each case, gene silencing results from destruction of mRNA that is 
complementary to the input siRNA (2) or the siRNA molecules created by Dicer cleavage of 
longer dsRNA (3) or shRNA (1) molecules. Dicer = cytoplasmic nuclease. From (Kim, 2005). 
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In non-mammalian systems, introducing or expressing long double stranded RNA 
(dsRNA) triggers the RNAi pathway (Figure 25, pathway 3). The cytoplasmic nuclease Dicer 
first cleaves the long dsRNA into 21–23 bp small interfering RNAs (siRNAs), then unwind 
and assemble into RNA-induced silencing complexes (RISCs). The antisense siRNA strand 
guides RISC to complementary RNA molecules, and RISC cleaves the mRNA, leading to 
specific gene silencing. Since most mammalian cells mount a potent antiviral response upon 
introduction of dsRNA longer than 30 bp, researchers induce RNAi in these systems by either 
transfecting cells with siRNAs (typically 21 bp RNA molecules with 3’ dinucleotide 
overhangs) or by using DNA-based vectors to express short hairpin RNAs (shRNAs) that are 
processed by Dicer into siRNA molecules (Figure 25, pathways 2 and 1, respectively). 
In this study, two main approaches for inducing RNAi into mammalian cells were 
applied: siRNAs (pathway 2) and shRNA expression vectors (pathway 1) (Figure 25). Knock-
down of MIF, Jab1/CSN5 and VCP was aimed to elucidate the function of these genes in 
specific pathways and also to define the role of Jab1/CSN5-VCP interaction in different 
cellular functions.  
5.5.1. Knock-down of MIF, VCP and Jab1/CSN5 with the shRNA pSUPER vector 
 
 The pSUPER RNAi System was used to cause efficient and specific down-regulation 
of gene expression to inactivate the three genes MIF, VCP and Jab1/CSN5 in NIH 3T3, 264.7 
RAW macrophages and HEKT293 cells, respectively (see details in 4.3.5).  
5.5.2. Knock-down of VCP and Jab1/CSN5 with siRNAs 
 
 To show a functional role of Jab1/CSN5 and VCP in the turnover of UPS proteins, 
Jab1/CSN5 and VCP gene expression were silenced transiently by using specific siRNAs. 72 
h after transfection, HEK293T lysates were examined by immunoblotting. Efficient 
knockdowns were obtained with Jab1/CSN5 and VCP-siRNAs resulting in almost complete 
suppression of Jab1/CSN5 and VCP expression. The scrambled control siRNA had no effect 
(Figure 26). Knock-down of Jab1/CSN5 suppressed CSN1 expression as well, which supports 
the previous finding that the CSN5 subunit affects assembly of the total CSN (Naumann et al., 
1999). Thus, removal of a single CSN subunit is efficient to destabilize the CSN complex and 
also reduce the level of other CSN related subunits. To confirm the impaired function of the 
CSN resulting from the knock-down of Jab1/CSN5, the level of Iκβα, a well known UPS 
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substrate was investigated. Notably, the amount of Iκβα protein was increased in cells 
showing a knock-down of Jab1/CSN5 (Figure 26A). Furthermore, in line with data published 
previously (Lue et al., 2007), a decrease in MIF expression and an increase of pAKT in 
Jab1/CSN5 knock-down cells were observed. This indicates that Jab1/CSN5 regulates MIF 
expression via AKT pathway.  
 
 
 
Figure 26: Effect of silencing of Jab1/CSN5 and VCP on selected proteins. 
(A) HEK293T cells were transiently transfected with either Jab1/CSN5 siRNA or with a 
scrambled siRNA (control). After 72 h cell lysates from control and Jab1/CSN5 knockdown 
cells were analyzed by immunoblotting. Immunodetection of Jab1/CSN5, CSN1, Iκβα, MIF 
and pAKT (see indicated panels), was performed using specific antibodies. (B) HEK293T 
cells were transiently transfected either with VCP siRNA or a scrambled control siRNA. 
Efficient knockdown of VCP (indicated panel) was analyzed in cell lysates by 
immunoblotting. Immunodetection of ubiquitin and VCP were performed using specific 
antibodies. β-actin served as control for equal sample loading. 
 
 To further investigate the impact of VCP knockdown on the assembly of 
ubiqutinylated proteins, HEK293T cells were transfected with either VCP siRNA or a 
scrambled control siRNA. Knockdown of VCP caused an accumulation of ubiquitinylated 
proteins confirming the previous result that VCP is a key chaperone targeting ubiquitinylated 
proteins to the proteasome (Dai et al., 1998). 
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5.6. Expression and purification of His-VCP and GST-Jab1/CSN5  
5.6.1. Expression of His-VCP and GST-Jab1/CSN5 
 
pET28a (+)-VCP and pGEX-4T1-Jab1/CSN5 constructs were used to transform E. coli 
BL21 (DE3) bacterial cells to express His-tagged VCP and GST-tagged Jab1/CSN5. One 
clone from the successfully transformed bacteria was selected for protein expression. For 
determining the optimal conditions for protein expression, bacterial VCP and Jab1/CSN5 
protein expression were induced with 0.5 mM IPTG at 37°C. The fusion proteins appeared as 
the major bacterial proteins 3h after induction (Fig. 27A and B; arrows).  
 
 
 
Figure 27: Expression of His-tagged VCP and GST-tagged Jab1/CSN5 in E. coli.  
500 ml culture of E. coli BL21 (DE3) carrying the VCP expression plasmid (A, lane 1) and 
the Jab1/CSN5 expression plasmid (B, lane 1) were induced with 0.5 mM IPTG at 37°C. 3 h 
after induction (lane 2), cells were treated with 1 mg/ml lysozyme and DNAse I (lane 3). 
Supernatants of the lysated cells (lane 4) were discarded. Resuspended pellets containing 
inclusion bodies (lane 5) were incubated with denaturation buffer and centrifuged (lane 6) 
again. The cleared lysate (lane 7) was dialyzed against PBS. Aliquots of each fraction were 
separated by 12.5% SDS-PAGE. The gel was stained with colloidal Coomassie blue after 
electrophoresis. (M) = molecular weight marker (kD). 
5.6.2. Purification of His-VCP and GST-Jab1/CSN5 
 
 His-VCP protein was affinity purified using Ni-NTA agarose beads, whereas the 
GST–Jab1/CSN5 protein was purified using a glutathion agarose column. Eluted fractions 
were collected and the purity of each fraction was subsequently investigated by SDS-PAGE 
(Figure 28A and B).  
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Figure 28: Purification of His tagged VCP and GST tagged Jab1/CSN5 
An aliquot from each eluted fraction (lane 1 to 6) was separated by 12.5% SDS-PAGE 
subsequently stained with Coomassie blue.  
 
5.7. MIF modulates binding between Jab1/CSN5 and VCP 
  
A previous study demonstrated that MIF binds to the MPN domain of Jab1/CSN5 
(Burger-Kentischer et al., 2005). In this study, it was shown that the MPN domain of 
Jab1/CSN5 also interacts with VCP. Since VCP and MIF bind to the same domain of 
Jab1/CSN5, it is suggested that MIF and VCP could compete for binding to Jab1/CSN5. To 
examine whether MIF could competitively affect the interaction between Jab1/CSN5 and 
VCP, HEK293T cells were transfected with pCIneo-Jab1/CSN5, FLAG-VCP and increasing 
amounts of pCMV-MIF. Cell lysates from transfected cells were subjected to VCP-IP (Figure 
29A). Indeed, increasing amounts of MIF decreased Jab1/CSN5 association with VCP (see 
indicated panel in figure 29A). This study proposes that MIF competes with VCP for 
Jab1/CSN5 binding. Conversely, transfecting cells with pCIneo-Jab1/CSN5, pCMV-MIF and 
increasing amounts of FLAG-VCP decreased Jab1/CSN5 interaction with MIF (Figure 29B).  
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Figure 29: Competition between MIF and VCP in binding to Jab1/CSN5. 
(A) HEK293T cells were transfected with Jab1/CSN5, VCP and either vector (v) or 
increasing amounts of MIF. Cell lysates were used for immunoprecipitation of VCP. 
Immunoprecipitated proteins were separated by SDS-PAGE and probed with antibodies 
directed against Jab1/CSN5, VCP, MIF and β-actin. (B) HEK293T cells were transfected with 
Jab1/CSN5, MIF and either vector (v) or increasing amounts of VCP. MIF was 
immunoprecipitated from cell lysates and precipitated proteins were detected by probing with 
antibodies directed against Jab1, MIF, VCP and β-actin. Input: 5% of cell lysate used for IP. 
 
 
Taken together, these results indicate that MIF decreases Jab1/CSN5 binding to VCP. 
Conversely, VCP also inhibited Jab1/CSN5 binding to MIF, showing competition of both 
molecules for binding to Jab1/CSN5.  
 
5.8. MIF activates VCP via AKT pathway 
 
It has been shown that MIF prevents apoptosis and enhances cell survival by direct 
activation of the AKT pathway (Lue et al., 2007). Moreover, VCP was shown as an important 
target of AKT mediated signaling and to be involved in AKT-mediated anti-apoptotic 
signaling (Vandermoere et al., 2006). The interaction between MIF and VCP found in this 
study raised the question whether MIF could enhance the phosphorylation of VCP via AKT 
signaling. Initially, the phosphorylation of AKT was examined in a time-dependent manner in 
NIH 3T3 cells. As recognized by PAS (Phospho AKT substrate) antibody MIF mediated AKT 
activation between 5 and 30 min was shown to cause VCP phosphorylation. (Figure 30). This 
finding strongly indicates that MIF induces the sustained phosphorylation of VCP. 
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Figure 30: Phosphorylation of AKT and AKT substrates by rMIF. 
Time course of AKT and VCP phosphorylation induced by exogenous rMIF (50 ng/ml) in 
NIH 3T3 fibroblasts. Dose response of phosphorylation of AKT and substrates (PAS) were 
analyzed by immunoblotting. Immunodetection of pAKT, AKT and VCP was performed 
using specific antibodies (see indicated right panel). Phosphorylation of VCP was detected 
using PAS (Phospho AKT substrate) antibody. AKT and VCP served as loading control. +, +: 
As a positive control PDGF (20 ng/ml) was used. 
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Table III: MALDI-MS identification of MIF interacting proteins from 1D-SDS-PAGE  
 
 Protein NCBI entry 
Matched 
peptides 
Note 
Ribosomal 
proteins Ribosomal protein S16 gi|33286940 
 
8  
 Ribosomal protein S3 gi|337514 7  
 Ribosomal protein L13 gi|33286940 5  
 Ribosomal protein S6 gi|337514 5  
 Ribosomal protein S9-like gi|21594169 5  
 Ribosomal protein S17 gi|950111 4  
 Rpl17 protein gi|28174920 3  
 Rps15a protein gi|56541088 3  
 Ribosomal protein L26 gi|56205563 3  
 Ribosomal protein L31 gi|56541054 3  
 Ribosomal protein S19 gi|62663652 3  
 Ribosomal protein L38 gi|12963655 2  
 Ribosomal protein S10 gi|13399310 1  
 60S ribosomal protein L21 gi|2500367 1  
 Ribosomal protein 10 gi|54035586 1  
 40S ribosomal protein SA gi|125970 1  
Mitochondrial 
proteins 
ATP synthase, H+ 
transporting  mitochondrial gi|1592878 12  
 ATP synthase beta-subunit gi|2623222   8  
 ADP,ATP carrier protein gi|423368   8  
 
Solute carrier family 25, 
 member 4 gi|20070838 7  
 Atp5b protein  gi|23272966 5  
 Sideroflexin 3   gi|15126554 3  
 
Mitochondrial carrier 
homolog 2 gi|24416581 3  
 
Voltage-dependent anion 
 channel 2  gi|33243895  3  
 
H(+)-transporting ATP 
synthase  gi|102  3  
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 Protein NCBI entry Matched 
peptides 
Note 
Heatschock 
proteins Hsc70-ps1 gi|56385 14  
 HSP 90-alpha (HSP 86) gi|1170383 11  
 Chaperonin subunit 2 (beta) gi|435839 5  
 Mortalin mot-2 gi|435839 5  
 Chaperonin containing TCP-1 gamma subunit gi|38969850 3  
 Chaperonin subunit 4 (delta) gi|32452050 4  
 CCT (chaperonin containing TCP-1) epsilon gi|468550 4  
 CCT (chaperonin containing TCP-1)beta gi|5295992 3  
ER 
proteins BIP gi|2598562 13 
ERAD 
component 
 T-complex protein 1  gi|13277861 8 ERAD component 
 Protein disulfide isomerase  gi|23958822  7 ERAD component 
 Clathrin  gi|51259242  5 VCP partner 
 Sec61 beta subunit gi|13324684  1 ERAD component 
Ca binding 
proteins Annexin A2   gi|13097 9  
 Annexin A1  gi|6754570         4  
 Troponin C-like protein gi|223036          4  
 S100 calcium binding gi|14789726        3  
Nuclear  
proteins Hist1h4h protein gi|27692960     5  
 Nucleophosmin 1 gi|55153941        4  
 Histone 1, H1e  gi|13430890        3  
 Hnrpm protein  gi|13543181        2  
 Heterogeneousnuclear ribonucleoprotein C gi|8393544 1  
Others Eukaryotic translation elongation factor 2  gi|13938072 13  
 Nonmuscle heavy chain myosin II gi|17978023        11  
 Lamin A, isoform A  gi|15929761        9  
 Eno1 protein   gi|54114937        8  
 ADP-ribosylation factor 1 gi|21594148        7  
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Protein NCBI entry Matched 
peptides 
Note 
 Plectin 1 gi|40849908        7  
 Transketolase  gi|11066098        7  
 Eukaryotic translation  elongation factor 1-delta gi|10442752 5  
 Mccc2 protein gi|20380367        5  
 AHNAK gi|37675525        6  
 Galectin 3  gi|33859580        5  
 Aldolase 1, A isoform  gi|27695278        4  
 B-cell receptor-associated gi|6671622         4  
 LDH-A   gi|535924          5  
 Rho GDP dissociation inhibitor (GDI) alpha gi|56541074   5  
 Eukaryotic translation elongation factor 1 gamma gi|53237111   4  
 p100 co-activator  gi|6009521         3  
 CPN10-like protein gi|8777943         3  
 Glutathione S-transferase gi|30931187        3  
 Prohibitin  gi|56206786        3  
 Ubiquitin gi|229532        2  
 Proteasome (macropain) subunit, alpha type 4 gi|12805051 2 
Proteasome 
subunit 
 Proteasome (macropain) subunit, beta type 5 gi|77415527 1 
Proteasome 
subunit 
 Trap1 protein gi|13905144 2 
 
 Peroxidase  gi|885932          2  
 Myosin IC gi|18204814        2  
 Kinesin family member gi|30794518        2  
 Voltage-dependent anion gi|13435771        2  
 Ehd2 protein  gi|20072042        2  
 Arpc4 protein gi|33244031        2  
 Thioredoxin 1 gi|14789654   2 MIF partner 
 Eukaryotic translation initiation factor 2 gi|16741332        1 
 
  Results 
 
 
 
Table IV: MALDI-MS identification of MIF interacting proteins from 2D-SDS-PAGE  
 
Spot Protein NCBI entry 
Mr 
(kDa) 
Matched 
peptides 
Note 
3 Peroxiredoxin 1 gi|56103807 22 10 
MIF and 
Jab1partner 
14 Valosin-containing protein gi|55217 89 12 
ERAD, UPS 
component 
4 Phosphoglycerate kinase 1 gi|987048 45 11  
5 
Heterogeneous nuclear 
ribonucleoprotein F gi|17390408 46 7  
6 Serine proteinase inhibitor gi|27806941 49 5  
11 Alpha-2-HS-glycoprotein gi|27806751 58 5  
2 
Eukaryotic translation 
initiation gi|124231 19 3  
20 Malate dehydrogenase gi|164543 36 4  
19 MIF gi|694108 11 4  
1 Troponin C-like protein gi|223036 17 2  
21 
AHA1, activator of heat 
shock 90kDa protein gi|12653109 38 2  
22 Pyrophosphatase gi|27754065 42 2  
23 
Acidic ribosomal 
phosphoprotein P0 gi|6671569 35 2  
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6. DISCUSSION 
 
 Macrophage migration inhibitory factor (MIF) was originally identified for its ability 
to inhibit the random migration of macrophages in vitro (Bloom and Bennett, 1966; David, 
1966). Later it was shown that MIF is involved in the pathogenesis of inflammatory diseases 
such as atherosclerosis, sepsis, asthma and rheumatoid arthritis (Calandra et al., 1994). MIF is 
an unusual cytokine since it is abundantly expressed by several cell types and stored in the 
cytoplasm (Bacher et al., 1997). Recent investigations identified CD74/CD44 as cellular 
surface receptor that mediates binding of extracellular MIF (Leng et al., 2003; Shi et al., 
2006). Albeit the majority of MIF research has focused on its role as pro-inflammatory 
mediator, recent studies showed that MIF functions are not limited to immune system. 
Elevated levels of MIF have been observed in several cancer tissues such as breast, bladder 
and lung cancer (Bando et al., 2002; Tomiyasu et al., 2002; Meyer-Siegler et al., 2006). 
Importantly, MIF was found to negatively regulate p53-mediated apoptosis (Hudson et al., 
1999). An attractive mechanism explaining the MIF-p53 relationship and MIF’s role in tumor 
development has been put forward (Nemajerova et al., 2007a). The authors propose that MIF 
plays a key role in regulating the DNA damage checkpoints which control cell cycle 
progression. It was found that MIF deficiency causes improper degradation of several cell 
cycle regulators such as p27, E2F1 and Cyclin A2. 
 MIF exerts its diverse biological effects by interacting with different proteins. Several 
of the MIF-interacting proteins identified to date are redox proteins or proteins which are 
directly connected to redox regulation (Thiele and Bernhagen, 2005). The interaction of the 
proliferation–associated gene product (PAG), a thiol-specific cellular antioxidant protein, with 
MIF results in inhibition of PAG’s antioxidant activity (Jung et al., 2001). In addition to PAG, 
hepatopoeitin is directly involved in MIF’s redox-modulating function (Li et al., 2004). 
Moreover, Bcl-2/adenovirus E1B interacting protein like (BNIPL), an apoptosis-associated 
protein was found to interact with MIF and it was suggested that BNIPL can inhibit MIF-
mediated cell proliferation (Shen et al., 2003). Recently, MIF was shown to be a functional 
noncognate ligand for the chemokine receptors CXCR2 and CXCR4 in inflammatory and 
atherogenic leukocyte recruitment (Bernhagen et al., 2007). 
 In a search for intracellular MIF-interacting proteins using the yeast two-hybrid 
system Jab1/CSN5 was identified (Kleemann et al., 2000). Jab1/CSN5 is a component of the 
COP9 signalosome (CSN) and possesses metalloprotease activity which targets SCF E3 
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Ubiquitin ligase and deconjugates Nedd8 from cullins (Cope et al., 2002; Zhou et al., 2003; 
Petroski and Deshaies, 2005). A balanced neddylation status of its cullin component seems to 
be required for correct SCF E3 ligase activity. It was proposed that MIF is able to control SCF 
activty via binding to Jab1/CSN5 (Nemajerova et al., 2007a). 
 Although several MIF-interacting proteins were identified previously, the mechanism 
of MIF action and the role of interacting proteins in influencing MIF signaling pathways 
remain unclear and partially controversial. Therefore, my aim was to identify new MIF-
interacting proteins and to investigate the impact of MIF-MIF-interacting protein interactions 
on cellular functions.  
6.1. Identification of MIF interacting proteins 
 
 In this study, new MIF-interacting proteins were identified using an approach based on 
specific in vivo biotinylation of stably expressed MIF. Taking advantage of the high affinity 
of biotin to avidin, in vivo methods were developed to specifically biotinylate ‘bait’ proteins 
(Cronan, 1990; Smith et al., 1998; Beckett et al., 1999; de Boer et al., 2003). Tagged MIF was 
efficiently biotinylated in vivo and associated MIF-interacting proteins were purified by 
binding to streptavidin. Amongst the affinity-based purification methods, the biotin-avidin 
system has several advantages. Firstly, as shown here biotinylated MIF can be efficiently 
purified directly from crude cellular extracts in a single-step procedure, whereas other in vivo 
tagging methods like the tandem affinity purification tag (TAP) strategy require several 
purification steps (Rigaut et al., 1999). Secondly, unspecific binding is minimized due to the 
small number of endogenously occurring biotinylated proteins. Thirdly, the very strong 
affinity of biotin to avidin allows to choose the stringency of washing conditions. This 
reduces nonspecific background binding, although high stringency washing might also 
remove MIF-interacting proteins with low affinity. Indeed, a systematic comparison of 
different tags showed that biotinylation is the best approach in terms of efficiency and purity 
(Tucker and Grisshammer, 1996). Fourthly, the inclusion of a TEV protease cleavage site 
downstream of the biotinylation tag was used to specifically cleave bound protein complexes 
from streptavidin, while leaving endogenously biotinylated proteins bound to the matrix. 
Moreover, the biotinylated peptide tag did not interfere with the ability of MIF to bind to well 
established MIF-interacting proteins such as Jab1/CSN5 and peroxiredoxin-1 demonstrating 
the applicability of the method. 
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In vivo biotin tagging combined with affinity purification and mass spectrometry had 
not been applied yet to systematically identify MIF-interacting proteins. My thesis led to the 
identification of more than 50 new candidates. Some of the identified proteins are presumably 
transiently or indirectly associated with MIF and have therefore not been identified with other 
approaches like yeast two-hybrid assays that allow only the detection of direct binding 
partners, whereas in vivo biotin tagging enables the purification of whole complexes 
consisting of direct and indirect binding partners. 
 In addition to known MIF-interacting proteins, a number of components of the 
ubiquitin proteasome system such as VCP, clathrin, ubiquitin, proteasome subunit α4, β5 and 
of the endoplasmic reticulum associated protein degradation (ERAD) complex such as BIP, 
ERp57, Sec61 and T-complex protein 1 were identified in this study. Many proteins of 
eukaryotic cells undergo folding and modification in the lumen of the endoplasmic reticulum 
(ER). If processing is not succesfull, misfolded proteins and unassembled protein complexes 
are retro-translocated into the cytosol and degraded by the proteasome. This multi-step 
process is called ER associated degradation (ERAD) (Zhong et al., 2004). Recent studies 
revealed that a plethora of factors such as VCP, Ufd1, Npl4, E3 ubiquitin ligases, Derlin-1, -2, 
and -3, BIP, VIMP, Ubx2, etc. are involved in ERAD (Ye et al., 2001; Lilley and Ploegh, 
2005; Neuber et al., 2005; Schuberth and Buchberger, 2005; Mouysset et al., 2006; Oda et al., 
2006). Among these proteins the AAA ATPase valosin-containing protein (VCP) seems to be 
the key factor. 
 The high number of MIF binding partners in the UPS prompted us to further 
investigate the association of MIF and VCP. An important question is whether MIF regulates 
the ERAD pathway by modulating VCP-dependent extraction of proteins from the ER. In the 
absence of MIF, ERAD substrates may rapidly be extracted from the ER and shuttled to the 
proteasome for degradation. In the presence of MIF, it could compete with ubiquitinylated 
proteins or other VCP cofactors for binding to VCP, displacing cofactors from VCP in a 
competitive manner. This may slow down the extraction of ubiquitinylated proteins, so that 
they accumulate in the ER. An accumulation of ERAD substrates in the ER increases cellular 
stress and contributes to disease pathogenesis. Therefore, the interaction between MIF and 
VCP could be part of a homeostatic mechanism that modulates traffic through the ERAD 
pathway. Although there are no data showing that MIF monitors and coordinates the ERAD 
pathway, the identification of ERAD key regulators as MIF interactors makes MIF a potential 
candidate for such a regulatory protein.  
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A recent study (Nemajerova et al., 2007b) showed that MIF regulates the activity of 
cullin 1 containing SCF ubiquitin ligases. The activity of SCF is stimulated by the 
conjugation of a ubiquitin-like protein called Nedd8 to cullins (Bornstein et al., 2006). 
Deneddylation of cullins is achieved by the CSN with the Jab1/CSN5 subunit hydrolysing 
Nedd8 (Cope et al., 2002). MIF binding to Jab1/CSN5 regulates the cycle and activity of the 
SCF complex. Consistent with these findings, this thesis also provides evidence suggesting a 
putative role for MIF in the regulation of the UPS. 
 Another MIF-interacting protein that was identified is phosphoglycerate kinase-1 
(Pgk-1), an ATP-generating glycolytic enzyme that forms part of the glycolytic pathway. 
During glycolysis, Pgk-1 catalyzes the transfer of a high-energy phosphoryl group from the 
acyl phosphate of 1,3-diphosphoglycerate to ADP to produce ATP. Pgk-1 also catalyzes the 
reverse reaction during gluconeogenesis where 3-phosphoglycerate and ATP are converted to 
1,3-diphosphoglycerate and ADP (Hitzeman et al., 1980; Blake and Rice, 1981). Because 
Pgk-1 is a highly-expressed gene and its mRNA is relatively stable, it has been the subject of 
a large number of studies on mRNA stability and decay, protein structure, folding, and 
kinetics as well as on hypoxia, tumorigenesis and wound healing. Hypoxia inducible 
transcription factor (HIF-1) plays an important role in controlling the glycolytic pathway 
when cells are exposed to low oxygen. Recently, HIF-1α was shown to up-regulate Pgk-1 as 
well as the glucose transporter type 1(GLUT1) and hexokinase 1(HK1) (Luo et al., 2006). In 
addition, intracellular pH decreases as a result of lactate accumulation caused by accelerated 
glycolysis. Because intracellular acidosis triggers apoptosis, blocking increased glycolytic 
activity by down regulating HIF-1α reduces apoptosis of the hypoxic cells. Interestingly, it 
was shown that the MIF gene contains a Hypoxia Response Element (HRE) within its 
promoter and is induced under hypoxic conditions (Koong et al., 2000; Bacher et al., 2003; 
Yao et al., 2005; Maity and Koumenis, 2006). During tissue injury, which leads to hypoxia, 
an essential part of the inflammatory response is the influx of monocytes/macrophages 
(Karhausen et al., 2005). In fact, knockout of HIF-1α was shown to cause a profound 
impairment in myeloid cell motility, invasiveness and bacterial killing (Cramer et al., 2003). 
Therefore, HIF-1α seems to control the function of myeloid cells in an inflammatory 
environment. HIF-1α could upregulate MIF to attract inflammatory cells in regions of 
hypoxia/inflammation. Moreover, MIF has been identified as a hypoxia-induced gene in 
cancer cells (Koong et al., 2000; Baugh et al., 2006). Based on these findings, both Pgk-1 and 
MIF seem to play critical roles in hypoxia providing a functional link between MIF and Pgk-
1.  
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 Other studies also support a functional role for the interaction between MIF and Pgk-1. 
Initially, MIF was shown to regulate glucose-induced insulin release in an autocrine fashion 
(Waeber et al., 1997). In perfusion studies performed with isolated rat islets of Langerhans, 
immunoneutralization of MIF reduced the glucose induced insulin secretion response by 39% 
(Waeber et al., 1997). Soon after, MIF was shown to increase the synthesis of fructose 2,6-
bisphosphate and cellular glucose uptake (Benigni et al., 2000). MIF is also found to be 
released by the ischaemic heart, where it stimulates the AMP-activated protein kinase, an 
important regulator of both glycolysis and glucose uptake during cellular stress (Miller et al., 
2008).  
The interaction between MIF and the newly identified proteins was verified by co-
immunoprecipitation and co-localization studies. Since the interaction between MIF and VCP 
was found in total cellular extracts of NIH 3T3 cells, immunohistochemical analysis revealed 
the presence of both proteins in the cytoplasm. A close association of the two proteins in the 
cytoplasm of NIH 3T3 cells was examined by fluorescence resonance energy transfer (FRET) 
combined with double-labeling indirect immunofluorescence. Although both proteins were 
found to co-localize in the cytoplasm, no significant FRET signal was detected indicating that 
MIF and VCP are not in close proximity excluding a direct interaction. However, FRET in 
combination with fluorescence labeled antibodies has limitations. For example, resonance 
energy transfer depends on the proper orientation of donor and acceptor. If this is 
unfavourable, FRET does not occur even if the proteins interact. In other words, a negative 
FRET result does not prove non-interaction. But also by using surface plasmon resonance 
analysis no interaction between MIF and VCP could be detected. Moreover, pull-down 
experiments were performed in vivo with ectopically expressed MIF and deletion mutants of 
VCP. However, none of the VCP domains interacted with MIF supporting the results of 
FRET and surface plasmon resonance analyses, which suggest an indirect interaction between 
MIF and VCP, potentially via a cofactor. Amongst these, a likely candidate is Jab1/CSN5 
since VCP and Jab1/CSN5 are both involved in the UPS and MIF interacts with Jab1/CSN5. 
6.2. Jab1/CSN5 directly interacts with VCP in vivo and in vitro 
 
In order to confirm whether Jab1/CSN5 is a linking cofactor between MIF and VCP, a 
putative direct interaction between Jab1/CSN5 and VCP was investigated. VCP possesses two 
consecutive AAA ATPase domains (called D1 and D2) and an N-terminal domain (N-
domain). The way how VCP associates with cofactors and ubiquitinylated substrates is an 
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area of active research and two possible mechanisms have been suggested. VCP can bind to 
proteins directly via its N-domain (Dai and Li, 2001) or indirectly through cofactors (Rape et 
al., 2001; Meyer et al., 2002; Hartmann-Petersen et al., 2004; Schuberth et al., 2004; Richly et 
al., 2005) as shown for ubiquitinylated substrates and other proteins. Indeed, the second 
mechanism may be more common as numerous VCP substrate-recruiting and -processing 
cofactors have been identified recently, which possess ubiquitin-binding domains and usually 
interact with VCP through its N-domain. For mapping the interface on VCP, deletion 
constructs were used for ectopic expression of the N-terminal domain (N), the two individual 
ATPase domains (D1, D2) and the combined N and D1 domains (ND1). After 
immunoprecipitation of Jab1/CSN5 neither the N-domain alone, nor the single D1 or D2 
domains were co-precipitated. Only the ND1 protein was able to bind to Jab1/CSN5 albeit 
with less affinity than the wild type protein indicating that it is sufficient for specific binding 
but that residues in D2 are further contributing to binding affinity. Most substrate-recruiting 
and –processing cofactors of VCP use the S3/S4 loop of a UBX domain (Jentsch and Rumpf, 
2007) for binding into a hydrophobic pocket that separates the N-domain of VCP into two 
subdomains (Dreveny et al., 2004). Jab1/CSN5 appears to be the first cofactor that is using an 
MPN core domain instead when interfacing with VCP. 
 To further validate a direct interaction between Jab1/CSN5 and VCP, pull-down 
experiments with purified recombinant proteins in vitro showed that the interaction between 
Jab1/CSN5 and VCP occurs directly without the need for a cofactor.  
 In another line of the study, FRET-CSLM analysis was used to confirm the interaction 
between Jab1/CSN5 and VCP. Significant FRET occured in the cytoplasm, indicating that 
VCP and Jab1/CSN5 must be closer than 10 nm in this compartment. There was no indication 
of co-localization in the nucleus. As reported previously, this thesis confirmed that 
Jab1/CSN5 is evenly distributed over the nucleus and cytoplasm whereas VCP is mainly 
located in the cytoplasm (Oh et al., 2006; Vandermoere et al., 2006). 
6.3. Jab1/CSN5 binds to ubiquitinylated proteins via its MPN domain 
 
 Ubiquitin is a 76-amino-acid polypeptide conjugated to proteins via an isopeptide 
bond between the C-terminus of ubiquitin and specific lysine residues in the ubiquitinylated 
protein. Ubiquitin can be attached to proteins as a monomer or as a polyubiquitin chain. Many 
studies show that ubiquitin and ubiquitinylation of substrates are involved in many biological 
functions such as protein degradation, endocytosis, protein sorting, subnuclear trafficking, and 
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gene expression (Pickart, 2001b). Lys48-linked polyubiquitin chains are the principal 
proteasomal targeting signal, while Lys63-linked chains appear to be nonproteolytic signals 
(Finley, 2001; Pickart, 2001b). Recent progress in the discovery of new biological roles for 
ubiquitinylation has gone hand in hand with the discovery of proteins possessing ubiquitin-
binding domains (Hicke et al., 2005; Harper and Schulman, 2006).  
 
Amongst these ubiquitin binding domains, JAMM motifs within MPN domains can 
have different functions. Whereas the JAMM motif of Jab1/CSN5 acts as a NEDD8 
isopeptidase, the motifs of RPN 11 and AMSH function as ubiquitin isopeptidases 
(McCullough et al., 2004). Contrary to these enzymatic examples, the JAMM motif of Mov 
34 is unable to complex a zinc ion and is proposed to have primarily a structural role like in 
the pre-mRNA splicing factor Prp8p whose inactive JAMM motif was shown to be a new 
ubiquitin binding domain (Bellare et al., 2006). Therefore, it was tested if Jab1/CSN5, apart 
from being a NEDD8 isopeptidase, can have other functions and binds K48-oligoubiquitin 
chains. Because Jab1/CSN5 is largely insoluble when produced in various expression 
systems, a strategy was developed here to refold guanidine HCl denatured GST-CSN5 by 
using the aggregation suppressor arginine and folding enhancer sucrose (Tresaugues et al., 
2004). Refolded GST-Jab1/CSN5 was immobilized on glutathione Sepharose beads and 
incubated with K48-linked polyubiquitin chains Ub(2–7). Jab1/CSN5 interacted with Ub2-7 
and showed a preference for Ub3 and 4. The positive control His-VCP that is known to bind 
polyubiquitin (Dai and Li, 2001) showed a very similar binding pattern.  
To investigate if binding of polyubiquitin is mediated by the JAMM motif, Myc-
tagged Jab1/CSN5 and its mutants were ectopically expressed in HEK 293T cells. The wild 
type protein and the 1-191 mutant containing the entire MPN domain (54-191) were able to 
bind to ubiquitinylated proteins. Importantly, also the 110-191 mutant harbouring the JAMM 
motif (129-175) but missing large parts of the MPN core (54-142) (Burger-Kentischer et al., 
2005) as well as the conserved glutamate 76 (Cope et al., 2002) could still interact with 
ubiquitinylated proteins albeit with slightly lower affinity. In contrast, the mutant 1-110 that 
does not contain the JAMM motif lost binding. Therefore, in addition to conferring NEDD8 
isopeptidase activity the JAMM motif of Jab1/CSN5 binds polyubiquitin but does not 
depolymerize it. Thus, this thesis supports previous experiments suggesting that the JAMM 
motif possesses ubiquitin deconjugation but not depolymerizing activity (Groisman et al., 
2003; Hetfeld et al., 2005) 
On the other hand, VCP has also been shown to interact with ubiquitinylated 
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substrates, to transfer them to the proteasome and to affect the degradation of ERAD and UPS 
substrates (Ghislain et al., 1996; Dai et al., 1998; Dai and Li, 2001; Jarosch et al., 2002). In 
contrast to the data presented here that VCP binds to ubiquitinylated proteins (Dai and Li, 
2001; Meyer et al., 2002) other studies showed little to no interaction (Doss-Pepe et al., 
2003). 
6.4. Jab1/CSN5 and VCP bind to the proteasome  
 
 Like Jab1/CSN5, RPN 11, the Jab1/CSN5 paralog in the proteasome lid, contains a 
JAMM/MPN+ motif, which constitutes the major de-ubiquitinylation activity of the 26S 
proteasome (Verma et al., 2002). Therefore, the question arose whether VCP can also bind to 
RPN 11. Total protein extracts from HEK 293T cells were separated by Sephacryl S-200 gel 
filtration chromatography and fractions were immunoblotted for VCP, RPN 11 and 
Jab1/CSN5. RPN 11 containing fractions were found to also contain VCP and Jab1/CSN5 
indicating that both proteins could indeed interact with the proteasome subunit RPN 11. 
Earlier studies had shown an association of VCP with the 26S proteasome (Dai et al., 1998), 
however, it remained unclear which subunit of the proteasome is associating with VCP. 
Although the functional relevance of a VCP-RPN 11 interaction was not investigated here the 
result suggests that ubiquitinylated proteins bound to VCP are transported to the proteasome 
where VCP interacts with RPN11 (Elsasser and Finley, 2005).  
6.5. Competition between MIF and VCP  
 
Binding experiments in mammalian cells revealed that the N terminal region together 
with the first ATPase domain D1 (i.e. ND1) of VCP is involved in the association with the 
MPN domain of Jab1/CSN5. It should be noted that other adaptors of VCP like p47, Ufd1p, 
SVIP and ataxin3 (Nagahama et al., 2003; Bruderer et al., 2004; Zhong et al., 2004) also bind 
to the ND1 domain of VCP. Likewise, the MPN domain of Jab1/CSN5 also binds to other 
proteins (Burger-Kentischer et al., 2005). Individual adaptors can occupy the same site on 
VCP or Jab1/CSN5, thereby preventing the binding of other proteins in a competitive manner. 
Indeed, increasing amounts of MIF decreased the amount of Jab1/CSN5 associated with VCP. 
Conversely, VCP also inhibited Jab1/CSN5 binding to MIF suggesting competition of both 
proteins for binding to Jab1/CSN5. Therefore, these results provide evidence for the 
hypothesis that MIF and VCP compete for binding to Jab1/CSN5.  
 Moreover, it is tempting to speculate that other adaptors of VCP (such as SVIP, p47, 
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etc.) can also compete with Jab1/CSN5 for binding to the ND1 domain of VCP. 
 
 
 
 
6.6. Jab1/CSN5 regulates the association of VCP with polyubiquitin  
 
 VCP binds to ubiquitinylated proteins and targets them to the proteasome. The fate of 
the ubiquitinylated substrates bound to VCP is defined by VCP partners referred to as 
substrate recruiting and processing factors (Rumpf and Jentsch, 2006; Jentsch and Rumpf, 
2007). Substrate-processing cofactors determine if ubiquitinylated substrates are 
polyubiquitinylated promoting proteasomal degradation, stably maintain their ubiquitinylation 
status or are de-ubiquitinylated and released from the complex. 
 To elucidate whether the interaction between Jab1/CSN5 and VCP results in 
deubiquitinylation of VCP bound proteins, HEK293T cells were transfected with wt-
Jab1/CSN5 and the JAMM mutant of Jab1/CSN5. Cell lysates were used for 
immunoprecipitation of FLAG-VCP in vivo. Polyubiquitin conjugated proteins bound to VCP 
were found to accumulate in JAMM mutant transfected cells, whereas no significant change 
was observed in wild type Jab1/CSN5 transfected cells.  
 Similarly, when CSN1 and Jab1/CSN5 were efficiently knocked down by RNAi, 
which leads to destabilization of the CSN polyubiquitinylated proteins accumulated on VCP. 
In conclusion, the JAMM motif of Jab1/CSN5 and a functional CSN complex are required for 
the deubiquitinylation of ubiquitinylated substrates bound to VCP. Because the CSN is 
associated with the deubiquitinase USP15 (Hetfeld et al., 2005) this thesis also demonstrated 
that knock down of USP15 caused the accumulation of polyubiquitinated proteins bound to 
VCP. Therefore, the activity of USP15 is involved in determining the fate of substrates bound 
to VCP.  
The functionality of the knockdowns was exemplarily shown for Jab1/CSN5. 
Knockdown significantly increased the fraction of neddylated cullin 1 as a functional CSN is 
lacking due to inapproriate amounts of CSN1 or 5 resulting in defective deneddylation. The 
same effect was observed when the JAMM mutant of Jab1/CSN5 was overexpressed 
demonstrating that the mutant protein is indeed compromising CSN deneddylase activity. 
However, in line with a previous publication (Cope and Deshaies, 2006) neddylation of 
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Cullin1 in Jab1/CSN5 knockdown cells was not complete in HEK293T cells. This indicates 
the presence of other deneddylases which may partially compensate the impaired deneddylase 
activity of the CSN. Contrary to HEK293T cells, HeLa cells showed hyperneddylation of 
Cullin1 in Jab1/CSN5 knockdown cells together with reduced expression of Cullin1. It is at 
present unclear why knockdown of Jab1/CSN5 in HEK293T and in HeLa cells behave 
differently. Moreover, IκBα accumulated in the Jab1/CSN5 knockdown due to deregulated 
deubiquitinylation by USP15 (Schweitzer et al., 2007).  
 In accordance with other studies, this thesis shows that knockdown of single CSN 
subunits strongly interfered with CSN function (Peth et al., 2007a; Peth et al., 2007b; 
Schweitzer et al., 2007). For example, knockdown of Jab1/CSN5 causes a 50% 
downregulation of CSN1. Therefore, it appears that a Jab1/CSN5 knockdown causes the 
coordinated downregulation of the entire CSN and thus compromises the deubiquitinylase and 
deneddylase activity of the CSN so that polyubiquitinylated proteins keep associated with 
VCP.  
6.7. VCP interacts with the CSN complex 
  
 Because Jab1/CSN5 exerts its activities as part of the CSN complex, it was examined 
if VCP is interacting with the whole CSN. It is known that CSN1 co-precipitates with other 
subunits of the CSN complex such as CSN 2, 3, 5 and 8 (Tsuge et al., 2001). Total cell 
extracts from HEK 293T cells were used to precipate the CSN1 subunit of the CSN. VCP co-
precipitated with CSN1 as well as with Jab1/CSN5 indicating that VCP indeed is interacting 
with the entire CSN complex. This finding leads to the speculation that the CSN together with 
VCP could form a complex that may be called the CSN particle similar to lid and base of the 
proteasome that form regulatory particle (Figure 31A and B).  
 This implies that the proteasomal proteins RPN1, 2, 10 and 13 or paralogous proteins 
could be part of the CSN particle as well. Currently, VCP is considered as a molecular 
`gearbox´ that in conjunction with substrate-processing cofactors is able to regulate the 
ubiquitinylation status of substrates (Jentsch and Rumpf, 2007). Because this thesis has shown 
that the deneddylase activity of Jab1/CSN5 and the deubiquitinase (DUB) USP15 are 
involved in the regulation of the ubiquitinylation status of proteins recruited to VCP, it can be 
hypothesized that both activities are decisive for `switching gears´. Other DUBs could be 
involved as well as the CSN is associated with at least two different enzymes (Groisman et 
al., 2003; Hetfeld et al., 2005). A further level of control originates from the association of 
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1,3,4-trisphosphate 5/6-kinase and protein kinases CK2 and D with the CSN which could be 
involved in regulating the association of substrate-processing cofactors with VCP through 
phosphorylation. Therefore, it emerges the picture of a molecular machine that is extracting 
ubiquitinylated and abnormally folded proteins from larger protein complexes or membranes 
and decides on their fate by using VCPs N-terminal domain and the CSN as a hub for 
substrate-processing cofactors and regulatory enzymes. 
 As the discovery of the interaction of VCP with Jab1/CSN originated from a MIF 
interactome screen, results of this thesis suggest that MIF is likely to be involved in the 
regulation of the ubiquitinylation status of substrates through interaction with Jab1/CSN5 
(Figure 31).  
 
Figure 31: The CSN and VCP form a complex – the CSN particle - that is structurally 
similar to the 19S proteasome regulatory particle. (A) Schematic representation of the 26S 
proteasome (adapted from Elsasser and Finley, 2005). The 26S proteasome is composed of 
one core particle (blue) and two regulatory particles as indicated. The regulatory particle can 
be further subdivided into the lid (orange) and the base (red). The base contains six ATPases 
(Rpt1-6), and four non-ATPase subunits (Rpn1, Rpn2, Rpn10, Rpn13). The lid contains six 
PCI domain-containing proteins (Rpn3, Rpn5–7, Rpn9, and Rpn12) and two MPN domain-
containing proteins (Rpn8 and Rpn11). (B) Proposed model of the CSN particle in analogy to 
the proteasome regulatory particle. The CSN particle may represent an alternative form of the 
regulatory particle. The proteasomol proteins RPN1, 2, 10 and 13 could be part of the CSN 
particle as indicated here with a question mark (?) (C) MIF binds to Jab1/CSN5 and prevents 
it from interacting with VCP, a mechanism that is likely to be involved in the regulation of the 
ubiquitinylation status of substrates.   
 
6.8. Effect of VCP-Jab1/CSN5 interaction on IκBα degradation 
 
 IκBα was selected as a UPS test substrate for investigations as the role of VCP in 
targeting substrates to the proteasome was shown (Dai et al., 1998). Deubiqutinylation of 
IκBα via Jab1/CSN5 has already been examined by others (Schweitzer et al., 2007). Upon 
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TNFα stimulation, IκBα the inhibitor of NF-κB is hyperphosphorylated, then 
polyubiquitinylated and targeted to the proteasome for degradation. In order to show the 
relevance of the VCP-Jab1/CSN5 interaction on IκBα degradation, HEK293T cells were 
transfected either with Jab1/CSN5siRNA or controlsiRNA and subsequently stimulated with 
TNFα in a time dependent manner. In accordance with previous studies (Wang et al., 2006; 
Schweitzer et al., 2007), TNFα induced IκBα degradation was delayed following knockdown 
of Jab1/CSN5. Because Jab1/CSN5 deubiquitinylates VCP bound substrates such as IκBα, 
knockdown of Jab1/CSN5 expression by using siRNA transfection extends the time period of 
VCP–ubiquitinylated IκBα association. Taken together, these data conclusively show that the 
CSN not only controls the deubiquitinylation of IκBα, but also the association between VCP 
and ubiquitinylated IκBα.  
 Other laboratories also have shown that knockdown of Jab1/CSN5 using siRNA leads 
to delayed degradation of IκBα and reduced NF-κB activity in synovial fibroblasts of 
rheumatoid arthritis origin as well as in HeLa cells (Wang et al., 2006; Schweitzer et al., 
2007). Jab1/CSN5 was shown to be required for the survival of synovial fibroblasts and 
knockdown of Jab1/CSN5 caused a high level of apoptosis which was concordant with the 
accumulation of IκBα. Since MIF was shown to be involved in the pathogenesis of many 
inflammatory diseases such as rheumatoid arthritis and artherosclerosis, MIF may also 
activate NF-κB. Indeed, it was shown that MIF activates NF-κB in human mononuclear cells 
(Amin et al., 2006). Moreover, MIF was shown to regulate AP-1 activity, but not the NF-κB 
activity in NIH 3T3 cells (Kleemann et al., 2000). This NF-κB activation by MIF may be cell-
specific since different cell types were used in those studies. As MIF and Jab1/CSN5 are both 
involved in the NF-κB pathway, they represent potential therapeutic targets for the treatment 
of inflammatory diseases.  
6.9. MIF activates VCP via the AKT pathway 
 
 MIF has been shown to antagonize p53-dependent gene expression (Hudson et al., 
1999; Nemajerova et al., 2007a) and to enhance proliferation in various cell types. The 
inhibition of p53 by MIF requires serial activation of ERK1/2, cPLA2, cyclooxygenase 2 
(COX2) and prostaglandin E2 (PGE2) (Mitchell et al., 1999). Although MIF-induced ERK 
signaling contributes to the anti-apoptotic properties of MIF, a more direct mechanism on 
MIF mediated cell survival was shown on the AKT signaling pathway via a PI3K-dependent 
route (Lue et al., 2007).  
 91
         Discussion 
 92
 Activation of AKT by MIF showed MIF’s potent anti-apoptotic effects and is in 
accordance with MIF’s cytokine/growth factor-like activity profile in inflammation and 
cancer (Roger et al., 2003; Mitchell, 2004). Enhancement of cell survival by MIF through 
PI3K/AKT is in line with observations suggesting a role for PI3K in MIF-dependent 
endothelial cell migration and angiogenesis (Amin et al., 2006). Interestingly, VCP was 
shown as an important target of AKT mediated signalling and to be involved in AKT-
mediated anti-apoptotic pathways (Vandermoere et al., 2006). In order to examine whether 
MIF mediated AKT activation causes VCP phosphorylation, AKT activation was examined in 
a time-dependent manner in NIH 3T3 cells. This thesis shows that MIF-induced AKT 
activation leads to phosphorylation of AKT substrates amongst them VCP. Data were 
strengthed as MIF-induced VCP phosphorylation was studied separately in fibroblasts, 
HEK293T and HeLa cells.  
 VCP phosphorylation has been also examined by other authors. Tyrosine 
phosphorylation of VCP was suggested to play a role in membrane fusion and the 
presentation of polyubiquitinylated proteins to the proteosome (Rabouille et al., 1995; Madeo 
et al., 1998; Dai and Li, 2001). In another study, VCP tyrosine dephosphorylation caused 
destabilization of VCP/ER membrane association thereby promoting ER transitional assembly 
(Lavoie et al., 2000). Moreover, VCP tyrosine phosphorylation has been shown to regulate 
cell proliferation and apoptosis (Imamura et al., 2003). In accordance with these studies, MIF-
mediated VCP phosphorylation also appears to be involved in cell survival and anti-apoptotic 
pathways. 
     Summary 
 
7. SUMMARY 
 
 Macrophage migration inhibitory factor (MIF) is a conserved 12.5 kD protein that 
serves many critical functions in the regulation of gene expression, proliferation, apoptosis 
and development. Over the last few years evidence has accumulated that MIF may function in 
the inhibition of the deneddylase activity of the COP9 signalosome (CSN) by interacting with 
its subunit Jab1/CSN5. The target of the CSN deneddylase activity is the cullin component of 
SCF E3 ubiquitin ligases that are significantly more active when neddylated. These ligases are 
responsible for the selective ubiquitinylation of substrates which are hydrolysed in the 26S 
proteasome. The latter consists of a 19S reguatory and a 20S core particle. Thus, 
ubiquitinylating enzymes and the proteasome form the two main pillars of the ubiquitin 
proteasome system (UPS). To better understand the biological role of MIF in the UPS, a 
systematic interactome screen was performed in NIH3T3 cells that are constitutively 
expressing biotinylated MIF.  
Biotinylated MIF and its associated proteins were purified by streptavidin binding. 
Subsequent identification of MIF interacting proteins by mass spectrometry detected a 
number of already known MIF interacting proteins including MIF itself, peroxiredoxin 1 and 
RPS19, thus emphasizing the validity of the approach. Besides other new candidates, 
endoplasmic reticulum (ER) associated chaperones amongst them BiP, ERp57 Sec61ß and the 
AAA ATPase valosin-containing protein (VCP), which are all involved in ER-associated 
degradation were identified. As many new MIF interacting partners are involved in the UPS, 
further investigations were concentrated on the association of MIF with Jab1/CSN5 and VCP. 
Whilst the binding of MIF to VCP seems to be indirectly mediated by Jab1/CSN5, the 
interaction of VCP with Jab1/CSN5 is direct and robust as was verified independently by co-
immunoprecipitation (co-IP), in vitro pull-down assays and fluorescence resonance energy 
transfer experiments. 
The interaction interface between VCP and Jab1/CSN5 was investigated by transient 
transfection of wild type and mutant proteins followed by co-IP. It emerged that Jab1/CSN5 
associates with VCP via the core of its MPN domain that is contacting the N-terminal domain 
and the D1 domain of VCP. Its binding is independent of the JAMM motif harboring the 
NEDD8 isopeptidase activity. The JAMM motif was also shown to bind, but not to 
depolymerize poly-ubiquitinylated chains. Using gel filtration chromatography, VCP co-
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migrated with the CSN and co-IP experiments confirmed that the interaction of VCP is not 
restricted to Jab1/CSN5, but involves the whole CSN complex in the association. The CSN 
consists of eight proteins that all have paralogs in the 19S regulatory particle of the 
proteasome. VCP is a homohexameric ATPase with structural homology to the 
heterohexameric ring of ATPases in the 19S regulatory particle. 
 RNA interference mediated knockdowns demonstrated that the JAMM motif of CSN5, 
a functional CSN complex and the CSN-associated deubiquitinase USP15 are all required for 
deubiquitinylation of substrates bound to VCP.  
Taken together, these results suggest that the CSN together with VCP forms a 
complex. Apart from interacting with at least one deubiquitinylase, the CSN is also known to 
be associated with three kinases that could regulate the connection of substrate-processing 
cofactors with VCP via phosphorylation. Therefore, we hypothesize that the CSN together 
with VCP could have the function to extract ubiquitinylated and abnormal folded proteins 
from larger protein complexes or membranes and to determine their fate by means of 
associated substrate-processing cofactors and regulatory enzymes.  
 
 
  Zusammenfassung 
8. ZUSAMMENFASSUNG 
 
Der Makrophagen Migrations-Inhibitionsfaktor (MIF) ist ein konserviertes 12,5 kD großes 
Protein, das zahlreiche kritische Funktionen bei der Genexpression, der Proliferation, der 
Apoptose und der Entwicklung erfüllt. In den letzten Jahren wurde deutlich, dass eine 
wichtige Funktion von MIF in der Inhibition der Deneddylase-Aktivität des COP9-
Signalosoms (CSN) durch Interaktion mit seiner Untereinheit Jab1/CSN5 bestehen könnte. 
Substrat für die CSN Deneddylase-Aktivität ist die Cullin-Komponente von SCF E3-
Ubiquitin-Ligasen, die im neddylierten Zustand signifikant aktiver sind. Sie sind 
verantwortlich für die selektive Ubiquitinylierung von Substraten, die dann im 26S 
Proteasom, das aus einem 19S regulatorischen Partikel und einem 20S Kernpartikel besteht, 
hydrolysiert werden. Ubiquitinylierungsenzyme und das Proteasom bilden somit die beiden 
Hauptkomponenten des Ubiquitin-Proteasom-Systems (UPS). Um zu einem verbesserten 
Verständnis der  biologischen Rolle von MIF innerhalb des UPS beizutragen, wurde das MIF-
Interaktom mit Hilfe von NIH3T3-Zellen, die konstitutiv biotinmarkiertes MIF exprimieren, 
untersucht. 
 Biotinyliertes MIF und damit assoziierte Proteine wurden zunächst über Streptavidin-
Bindung aufgereinigt. Die Validierung der Methode erfolgte mittels Massenspektrometrie und  
der Identifizierung von einigen bereits bekannten MIF Interaktionspartnern wie MIF selbst, 
Peroxiredoxin 1 und RPS19. Zusätzlich wurden zahlreiche neue MIF-Interaktionspartner 
gefunden. Auffällig war, dass sich darunter viele mit dem Endoplasmatischen Retikulum (ER) 
assoziierte Chaperone wie BiP, ERp57,  Sec61ß und die AAA ATPase VCP befanden, die 
alle bei der ER-assoziierten Degradation eine Rolle spielen. Aufgrund der vielen in das UPS 
eingebundenen neu identifizierten Interaktionspartner konzentrierten sich die anschließenden 
Untersuchungen auf die Interaktionen zwischen MIF, Jab1/CSN5 und VCP. Die Ergebnisse 
dieser Arbeit zeigen, dass die Bindung zwischen MIF und VCP indirekt über Jab1/CSN5 
vermittelt wird, wogegen eine direkte und robuste Interaktion zwischen VCP und Jab1/CSN5 
durch Co-Immunpräzipitationen (Co-IPs), in vitro Pull-down-Assays sowie 
Fluoreszenzresonanz-Energietransfer-Untersuchungen bestätigt werden konnte. 
Die an der Interaktion zwischen Jab1/CSN5 und VCP beteiligten Domänen wurden 
mit Co-IP nach transienter Transfektion der Wildtyp-Proteine sowie einer Reihe von 
Mutanten untersucht. Hierbei wurde gefunden, dass Jab1/CSN5 mit Hilfe seiner MPN-
Kerndomäne an die N-terminale Domäne sowie die D1-Domäne von VCP bindet. Die 
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Bindung ist unabhängig vom JAMM-Motiv, das Teil der MPN Domäne ist und die NEDD8-
Isopeptidase-Aktivität vermittelt. Das JAMM-Motiv dagegen bindet auch oligo-
ubiquitinylierte Ketten, ohne diese jedoch depolymerisieren zu können. In  
Gelfiltrationsuntersuchungen co-migriert VCP mit dem CSN Komplex. Mit Co-IPs konnte 
gezeigt werden, dass nicht nur Jab1/CSN5, sondern der gesamte CSN-Komplex mit VCP 
interagiert. Der CSN-Komplex besteht aus acht Proteinen, die allesamt Paraloge im 19S 
regulatorischen Partikel des Proteasoms haben. VCP ist eine homohexamere ATPase, die 
strukturelle Ähnlichkeit mit dem heterohexameren Ring von ATPasen im 19S regulatorischen 
Partikel aufweist.  
  Durch RNA-Interferenz vermittelte Knockdowns konnte weiterhin gezeigt werden, 
dass das JAMM-Motiv von Jab1/CSN5, ein funktioneller CSN-Komplex sowie die CSN-
assoziierte Deubiquitinase USP15 sämtlich essentiell für die Deubiquitinylierung von an VCP 
gebundenen Substraten sind. 
 Zusammengenommen legen diese Ergebnisse nahe, dass das CSN mit VCP einen 
Komplex bildet. Neben der Assoziation mit mindestens einer Deubiquitinase (DUB) ist das 
CSN mit drei Kinasen assoziiert, die die Bindung von substratprozessierenden Cofaktoren an 
VCP durch Phosphorylierung regulieren könnten. Das CSN mit VCP könnte damit die 
Funktion aufweisen, ubiquitinylierte und fehlgefaltete Proteine aus größeren 
Proteinkomplexen oder Membranen zu extrahieren und über ihre weitere Verwendung mit 
Hilfe von substratprozessierenden Cofaktoren und regulatorischen Enzymen zu entscheiden. 
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